US20230018482A1 - End-capped polyisobutylene polyurethane - Google Patents

End-capped polyisobutylene polyurethane Download PDF

Info

Publication number
US20230018482A1
US20230018482A1 US17/951,682 US202217951682A US2023018482A1 US 20230018482 A1 US20230018482 A1 US 20230018482A1 US 202217951682 A US202217951682 A US 202217951682A US 2023018482 A1 US2023018482 A1 US 2023018482A1
Authority
US
United States
Prior art keywords
residue
diisocyanate
polymeric material
polyisobutylene
copolymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US17/951,682
Other versions
US11851522B2 (en
Inventor
Joseph T. Delaney
Andrew J. Ro
David R. Wulfman
Niraj Gurung
Patrick Willoughby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardiac Pacemakers Inc
Original Assignee
Cardiac Pacemakers Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiac Pacemakers Inc filed Critical Cardiac Pacemakers Inc
Priority to US17/951,682 priority Critical patent/US11851522B2/en
Assigned to CARDIAC PACEMAKERS, INC. reassignment CARDIAC PACEMAKERS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DELANEY, JOSEPH T., JR., RO, Andrew J., WILLOUGHBY, PATRICK, GURUNG, Niraj, WULFMAN, DAVID R.
Publication of US20230018482A1 publication Critical patent/US20230018482A1/en
Application granted granted Critical
Publication of US11851522B2 publication Critical patent/US11851522B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00Polymeric products of isocyanates or isothiocyanates
    • C08G18/06Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/40High-molecular-weight compounds
    • C08G18/62Polymers of compounds having carbon-to-carbon double bonds
    • C08G18/6204Polymers of olefins
    • C08G18/6208Hydrogenated polymers of conjugated dienes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/16Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/04Macromolecular materials
    • A61L29/041Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • A61L31/048Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/12Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L31/125Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L31/129Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix containing macromolecular fillers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/143Stabilizers
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00Polymeric products of isocyanates or isothiocyanates
    • C08G18/06Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08Processes
    • C08G18/10Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step
    • C08G18/12Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step using two or more compounds having active hydrogen in the first polymerisation step
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00Polymeric products of isocyanates or isothiocyanates
    • C08G18/06Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/2805Compounds having only one group containing active hydrogen
    • C08G18/285Nitrogen containing compounds
    • C08G18/2865Compounds having only one primary or secondary amino group; Ammonia
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00Polymeric products of isocyanates or isothiocyanates
    • C08G18/06Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/40High-molecular-weight compounds
    • C08G18/4009Two or more macromolecular compounds not provided for in one single group of groups C08G18/42 - C08G18/64
    • C08G18/4063Mixtures of compounds of group C08G18/62 with other macromolecular compounds
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00Polymeric products of isocyanates or isothiocyanates
    • C08G18/06Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/40High-molecular-weight compounds
    • C08G18/48Polyethers
    • C08G18/4804Two or more polyethers of different physical or chemical nature
    • C08G18/4808Mixtures of two or more polyetherdiols
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00Polymeric products of isocyanates or isothiocyanates
    • C08G18/06Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/40High-molecular-weight compounds
    • C08G18/48Polyethers
    • C08G18/4854Polyethers containing oxyalkylene groups having four carbon atoms in the alkylene group
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00Polymeric products of isocyanates or isothiocyanates
    • C08G18/06Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/40High-molecular-weight compounds
    • C08G18/62Polymers of compounds having carbon-to-carbon double bonds
    • C08G18/6204Polymers of olefins
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00Polymeric products of isocyanates or isothiocyanates
    • C08G18/06Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/70Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
    • C08G18/72Polyisocyanates or polyisothiocyanates
    • C08G18/74Polyisocyanates or polyisothiocyanates cyclic
    • C08G18/76Polyisocyanates or polyisothiocyanates cyclic aromatic
    • C08G18/7657Polyisocyanates or polyisothiocyanates cyclic aromatic containing two or more aromatic rings
    • C08G18/7664Polyisocyanates or polyisothiocyanates cyclic aromatic containing two or more aromatic rings containing alkylene polyphenyl groups
    • C08G18/7671Polyisocyanates or polyisothiocyanates cyclic aromatic containing two or more aromatic rings containing alkylene polyphenyl groups containing only one alkylene bisphenyl group
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00Polymeric products of isocyanates or isothiocyanates
    • C08G18/06Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/83Chemically modified polymers
    • C08G18/833Chemically modified polymers by nitrogen containing compounds

Definitions

  • the present disclosure relates to polymeric materials. More specifically, the disclosure relates to polyisobutylene-polyurethane block copolymers, methods for making polyisobutylene-polyurethane block copolymers, and medical devices containing polyisobutylene-polyurethane block copolymers
  • Polymeric materials are widely used in the field of medical devices.
  • polymeric materials such as silicone rubber, polyurethane, and fluoropolymers are used as coating and/or insulating materials for medical leads, stents, catheters, and other devices.
  • Block copolymers are polymeric materials made of alternating sections of polymerized monomers.
  • Polyisobutylene-polyurethane block copolymers are polymeric materials with many unique physical and mechanical properties. Exemplary properties, which may be particularly desirable in the field of medical devices, include thermal stability, chemical resistance, biocompatibility, and gas impermeability, among others.
  • incorporación of polymeric materials into implantable medical devices may be done by a variety of methods, depending on the specific application.
  • the polymeric material may be extruded at a temperature sufficient to cause the block copolymer to flow, but not high enough to cause the polymeric material to break down. That is, the material that forms the lead after the extrusion and cooling has largely the same structure as the original polymeric material.
  • solvent-based processing includes electrospraying, electrospinning, spray coating, dip coating, and force spinning. Essential to all solvent-based processing of polymeric materials is the ability to bring the polymeric material into solution while retaining the basic structure of the polymeric material.
  • Example 1 is a polymeric material including a polyisobutylene-polyurethane block copolymer.
  • the polyisobutylene-polyurethane block copolymer includes soft segments, hard segments, and end groups.
  • the soft segments include a polyisobutylene diol residue.
  • the hard segments include a diisocyanate residue.
  • the end groups are bonded by urea bonds to a portion of the diisocyanate residue.
  • the end groups include a residue of a mono-functional amine.
  • Example 2 is the polymeric material of Example 1, wherein the mono-functional amine is a primary amine or a secondary amine.
  • Example 3 is the polymeric material of either of Examples 1 or 2, wherein the mono-functional amine includes a C 3 to C 30 aliphatic chain.
  • Example 4 is the polymeric material of any of Examples 1-3, wherein the mono-functional amine is butylamine.
  • Example 5 is the polymeric material of any of Examples 1-4, wherein the soft segments are present in the copolymer in an amount of about 40% to about 70% by weight of the copolymer, and the hard segments are present in the copolymer in an amount of about 30% to about 60% by weight of the copolymer.
  • Example 6 is the polymeric material of any of Examples 1-5, wherein the diisocyanate residue includes 4,4′-methylene diphenyl diisocyanate residue.
  • Example 7 is the polymeric material of any of Examples 1-6, wherein the hard segments further include a chain extender residue.
  • Example 8 is the polymeric material of Example 7, wherein the chain extender residue is 1,4-butanediol residue.
  • Example 9 is the polymeric material of any of Examples 1-8, wherein the soft segments further include at least one of a polyether diol residue, a polyester diol residue, and a polycarbonate diol residue.
  • Example 10 is a medical device including the polymeric material of any of Examples 1-9.
  • Example 11 is a method of making a polymeric material.
  • the method includes heating a mixture of soft segment components and hard segment components to an elevated temperature to form a prepolymer, reacting a chain extender with the prepolymer to form a polymer, and reacting an end capping agent with at least one of: the prepolymer and the polymer to form the polymeric material.
  • the soft segment components include a polyisobutylene diol.
  • the hard segment components include a diisocyanate.
  • the end capping agent includes a mono-functional amine.
  • Example 12 is the method of Example 11, wherein the mono-functional amine is a primary amine or a secondary amine.
  • Example 13 is the method of either of Examples 11 or 12, wherein the mono-functional amine includes a C 3 to C 30 aliphatic chain.
  • Example 14 is the method of any of Examples 11-13, wherein the mono-functional amine is butylamine.
  • Example 15 is the method of any of Examples 11-14, wherein the diisocyanate is in stoichiometric excess with respect to the polyisobutylene diol and the chain extender, and the mono-functional amine is an at least equimolar amount with respect to the diisocyanate.
  • Example 16 is a polymeric material including a polyisobutylene-polyurethane block copolymer.
  • the polyisobutylene-polyurethane block copolymer includes soft segments, hard segments, and end groups.
  • the soft segments include a polyisobutylene diol residue.
  • the hard segments include a diisocyanate residue.
  • the end groups are bonded by urea bonds to a portion of the diisocyanate residue.
  • the end groups include a residue of a mono-functional amine including a C 3 to C 30 aliphatic chain.
  • Example 17 is the polymeric material of Example 16, wherein the mono-functional amine is a primary amine or a secondary amine.
  • Example 18 is the polymeric material of Example of either of Examples 16 or 17, wherein the mono-functional amine is butylamine.
  • Example 19 is the polymeric material of any of Examples 16-18, wherein the soft segments are present in the copolymer in an amount of about 40% to about 70% by weight of the copolymer, and the hard segments are present in the copolymer in an amount of about 30% to about 60% by weight of the copolymer.
  • Example 20 is the polymeric material of any of Examples 16-19, wherein the diisocyanate residue includes 4,4′-methylene diphenyl diisocyanate residue.
  • Example 21 is the polymeric material of any of Examples 16-19, wherein the hard segments further include a chain extender residue.
  • Example 22 is the polymeric material of Example 21, wherein the chain extender residue is 1,4-butanediol residue.
  • Example 23 is the polymeric material of any of Examples 16-22, wherein the soft segments further include at least one of: a polyether diol residue, a polyester diol residue, and a polycarbonate dial residue.
  • Example 24 a medical device including a polymeric material.
  • the polymeric material includes a polyisobutylene-polyurethane block copolymer.
  • the polyisobutylene-polyurethane block copolymer includes soft segments, hard segments, and end groups.
  • the soft segments include a polyisobutylene diol residue.
  • the hard segments include a diisocyanate residue.
  • the end groups are bonded by urea bonds to a portion of the diisocyanate residue.
  • the end groups include a residue of a mono-functional amine including a C 3 to C 30 aliphatic chain.
  • Example 25 is the medical device of Example 24, wherein the mono-functional amine is a primary amine or a secondary amine.
  • Example 26 is the medical device of either of Examples 24 or 25, wherein the mono-functional amine is butylamine.
  • Example 27 is the medical device of any of Examples 24-26, wherein the soft segments are present in the copolymer in an amount of about 40% to about 70% by weight of the copolymer, and the hard segments are present in the copolymer in an amount of about 30% to about 60% by weight of the copolymer.
  • Example 28 is the medical device of any of Examples 24-27, wherein the diisocyanate residue includes 4,4′-methylene diphenyl diisocyanate residue.
  • Example 29 is a method of making a polymeric material.
  • the method includes heating a mixture of soft segment components and hard segment components to an elevated temperature to form a prepolymer, reacting a chain extender with the prepolymer to form a polymer, and reacting an end capping agent with at least one of: the prepolymer and the polymer to form the polymeric material.
  • the soft segment components include a polyisobutylene diol.
  • the hard segment components include a diisocyanate.
  • the end capping agent includes a mono-functional amine including a C 3 to C 30 aliphatic chain.
  • Example 30 is the method of Example 29, wherein the mono-functional amine is a primary amine or a secondary amine.
  • Example 31 is the method of either of Examples 29 or 30, wherein the mono-functional amine is butylamine.
  • Example 32 is the method of any of Examples 29-31, wherein the diisocyanate is in stoichiometric excess with respect to the polyisobutylene diol and the chain extender, and the mono-functional amine is an at least equimolar amount with respect to the diisocyanate.
  • Example 33 is the method of any of Examples 29-32, wherein heating the mixture of the soft segment components and the hard segment components to an elevated temperature and reacting the chain extender with the heated mixture are in the presence of a tertiary amine catalyst.
  • Example 34 is the method of Example 29, wherein the diisocyanate includes 4,4′-methylene diphenyl diisocyanate.
  • Example 35 is the method of any of Examples 29-34, wherein the soft segment components further include a polytetramethylene oxide diol, the diisocyanate is in stoichiometric excess with respect to the polyisobutylene diol, the chain extender, and the polytetramethylene oxide diol, and the mono-functional amine is an at least equimolar amount with respect to the diisocyanate.
  • the soft segment components further include a polytetramethylene oxide diol
  • the diisocyanate is in stoichiometric excess with respect to the polyisobutylene diol
  • the chain extender and the polytetramethylene oxide diol
  • the mono-functional amine is an at least equimolar amount with respect to the diisocyanate.
  • FIG. 1 is a schematic diagram illustrating a first step of a process to produce polyisobutylene-polyurethane according to some embodiments of this disclosure.
  • FIG. 2 is a schematic diagram illustrating a second step of a process to produce polyisobutylene-polyurethane according to some embodiments of this disclosure.
  • FIG. 3 is a schematic diagram illustrating another process to produce polyisobutylene-polyurethane according to some embodiments of this disclosure.
  • FIG. 4 is a plot of dynamic viscosity as a function of concentration for polyisobutylene-polyurethane solutions according to some embodiments of this disclosure.
  • polyisobutylene-polyurethane block copolymers also referred to herein collectively as “PIB-PUR”
  • PIB-PUR is a thermoplastic polyurethane (TPUs) that contains hard and soft segments.
  • TPUs thermoplastic polyurethane
  • PIB-PUR is useful in a number of applications, including in medical devices used for insertion or implantation into a patient because they are hydrolytically stable and have good oxidative stability.
  • Polyurethanes are a family of copolymers that are synthesized from polyfunctional isocyanates (e.g., diisocyanates, including both aliphatic and aromatic diisocyanates) and polyols (e.g., macroglycols).
  • polyfunctional isocyanates e.g., diisocyanates, including both aliphatic and aromatic diisocyanates
  • polyols e.g., macroglycols
  • Commonly employed macroglycols include polyester diols, polyether diols and polycarbonate diols.
  • the macroglycols can form polymeric segments of the polyurethane.
  • Aliphatic or aromatic diols may also be employed as chain extenders, for example, to impart improved physical properties to the polyurethane.
  • the polyisobutylene urethane copolymer includes one or more polyisobutylene segments, one or more segments that includes one or more diisocyanate residues, optionally one or more additional polymeric segments (other than polyisobutylene segments), and optionally one or more chain extenders.
  • a “polymeric segment” or “segment” is a portion of a polymer.
  • the polyisobutylene segments of the polyisobutylene urethane copolymers are generally considered to constitute soft segments, while the segments containing the diisocyanate residues are generally considered to constitute hard segments.
  • the additional polymeric segments may include soft or hard polymeric segments.
  • soft and hard segments are relative terms to describe the properties of polymer materials containing such segments. Without limiting the foregoing, a soft segment may display a glass transition temperature (Tg) that is below body temperature, more typically from 35° C. to 20° C. to 0° C. to ⁇ 25° C. to ⁇ 50° C. or below.
  • Tg glass transition temperature
  • a hard segment may display a Tg that is above body temperature, more typically from 40° C. to 50° C. to 75° C. to 100° C. or above.
  • Tg can be measured by differential scanning calorimetry (DSC), dynamic mechanical analysis (DMA) and/or thermomechanical analysis (TMA).
  • DSC differential scanning calorimetry
  • DMA dynamic mechanical analysis
  • TMA thermomechanical analysis
  • the weight ratio of soft segments to hard segments in the polyisobutylene urethane copolymers of the various embodiments can be varied to achieve a wide range of physical and mechanical properties, and to achieve an array of desirable functional performance.
  • the weight ratio of soft segments to hard segments in the polymer can be varied from 99:1 to 95:5 to 90:10 to 75:25 to 50:50 to 25:75 to 10:90 to 5:95 to 1:99, more particularly from 95:5 to 90:10 to 80:20 to 70:30 to 65:35 to 60:40 to 50:50, and even more particularly, from about 80:20 to about 50:50.
  • the soft segment components can be about 40% to about 70% by weight of the copolymer, and the hard segment components can be about 30% to about 60% by weight of the copolymer.
  • the copolymer may include polyisobutylene in an amount of about 60% to about 100% by weight of the soft segments and a polyether, a polyester, or a polycarbonate in an amount of about 0% to about 40% by weight of the soft segments.
  • the copolymer may include soft segments in an amount of about 40% to about 70% by weight of the copolymer, of which polyisobutylene is present in an amount of about 60% to about 100% by weight of the soft segments and polyether is present in an amount of about 0% to about 40% by weight of the soft segments.
  • the copolymer may include soft segments in an amount of about 40% to about 70% by weight of the copolymer, of which polyisobutylene (e.g., a polyisobutylene diol residue) is present in an amount of about 70% to about 95% by weight of the soft segments and a polyether (e.g., polytetramethylene oxide diol residue) is present in an amount of about 5% to about 40% by weight of the soft segments.
  • polyisobutylene e.g., a polyisobutylene diol residue
  • a polyether e.g., polytetramethylene oxide diol residue
  • Diisocyanates for use in forming PIB-PUR of the various embodiments include aromatic and non-aromatic (e.g., aliphatic) diisocyanates.
  • Aromatic diisocyanates may be selected from suitable members of the following, among others: 4,4′-methylenediphenyl diisocyanate (MDI), 2,4′-methylenediphenyl diisocyanate (2,4-MDI), 2,4- and/or 2,6-toluene diisocyanate (TDI), 1,5-naphthalene diisocyanate (NDI), para-phenylene diisocyanate, 3,3′-tolidene-4,4′-diisocyanate and 3,3′-dimethyl-diphenylmethane-4,4′-diisocyanate.
  • MDI 4,4′-methylenediphenyl diisocyanate
  • TDI 2,
  • Non-aromatic diisocyanates may be selected from suitable members of the following, among others: 1,6-hexamethylene diisocyanate (HDI), 4,4′-dicyclohexylmethane diisocyanate (H12-MDI), 3-isocyanatomethyl-3,5,5-trimethylcyclohexyl isocyanate (isophorone diisocyanate or IPDI), cyclohexyl diisocyanate, and 2,2,4-trimethyl-1,6-hexamethylene diisocyanate (TMDI).
  • HDI 1,6-hexamethylene diisocyanate
  • H12-MDI 4,4′-dicyclohexylmethane diisocyanate
  • IPDI isophorone diisocyanate
  • cyclohexyl diisocyanate 2,2,4-trimethyl-1,6-hexamethylene diisocyanate
  • a polyether diol such as polytetramethylene oxide diol (PTMO diol), polyhexametheylene oxide diol (PHMO diol), polyoctamethylene oxide diol or polydecamethylene oxide diol, can be combined with a polyisobutylene diol and diisocyanate to form a polyisobutylene polyurethane copolymer.
  • PIB-PUR may have a generally uniform distribution of polyurethane hard segments, polyisobutylene segments and polyether segments to achieve favorable micro-phase separation in the polymer.
  • polyether segments may improve key mechanical properties such as Shore hardness, tensile strength, tensile modulus, flexural modulus, elongation tear strength, flex fatigue, tensile creep, and/or abrasion performance, among others.
  • the polyisobutylene diol may be a telechelic polyisobutylene diol formed from by carbocationic polymerization beginning with a difunctional initiator compound, such as 5-tert-butyl-1,3-bis(1-methoxy-1-methylethyl)benzene (hindered dicumyl ether).
  • a difunctional initiator compound such as 5-tert-butyl-1,3-bis(1-methoxy-1-methylethyl)benzene (hindered dicumyl ether).
  • PIB-PUR in accordance with the various embodiments may further include one or more optional chain extender residues.
  • Chain extenders can increase the hard segment length, which can in turn results in a copolymer with a higher tensile modulus, lower elongation at break and/or increased strength.
  • Chain extenders can be formed from aliphatic or aromatic diols, in which case a urethane bond is formed upon reaction with an isocyanate group.
  • Chain extenders may be selected from suitable members of the following, among others: 1,4 cyclohexanedimethanol, alpha,omega-alkane diols such as ethylene glycol (1,2-ethane diol), 1,4-butanediol (BDO), and 1,6-hexanediol.
  • Chain extenders may be also selected from suitable members of, among others, short chain diol polymers (e.g., alpha,omega-dihydroxy-terminated polymers having a molecular weight less than or equal to 1000) based on hard and soft polymeric segments (more typically soft polymeric segments) such as those described above, including short chain polyisobutylene diols, short chain polyether polyols such as polytetramethylene oxide diols, short chain polysiloxane diols such as polydimethylsiloxane dials, short chain polycarbonate diols such as polyhexamethylene carbonate diols, short chain poly(fluorinated ether) diols, short chain polyester dials, short chain polyacrylate dials, short chain polymethacrylate dials, and short chain polyvinyl aromatic) dials. Chain extenders may also be selected form suitable glycols, such as propylene glycol, dipropylene glycol, and tripropylene glycol.
  • the PIB-PUR may be synthesized and stored for a period of time until it is incorporated into the solvent processing.
  • the FIB-PUR may be stored for a period of days, weeks or months.
  • the PIB-PUR is dissolved in a solvent, such as, for example, 2,6-dimethylpyridine or tetrahydrofuran (THF), to obtain a desired concentration and/or viscosity of the resulting PIB-PUR solution.
  • the PIB-PUR solution can then be deposited onto a substrate, such as a medical device, by electrospraying, electrospinning, spray coating, dip coating, or force spinning.
  • the molecular weight (both the weight average molecular weight (Mw) and the number average molecular weight (Mn)) of the PIB-PUR can increase during the storage period.
  • the stored PIB-PUR forms a gel.
  • Such gels are that is no longer easily soluble in 2,6-dimethylpyridine or THF and thus, no longer suitable for solvent-based processing.
  • an end-capping agent that is a mono-functional amine can mitigate the increase in molecular weight due to extended storage time.
  • the addition of such an end capping agent to PIB-PUR that has been stored for an extended period of time can reverse the increase in molecular weight of the PIB-PUR.
  • the addition of such an end capping agent to PIB-PUR even after is has gelled and is no longer soluble in 2,6-dimethylpyridine or THF can break down the cross-links in the gel so that the PIB-PUR is soluble in 2,6-dimethylpyridine or THF.
  • a gel is defined as a substantially dilute cross-linked system which exhibits no flow when in a steady-state.
  • the mono-functional amine can include a C 3 to C 30 aliphatic chain that can be straight or branched, saturated or unsaturated, a primary amine or a secondary amine.
  • the mono-functional amine can be a butylamine or a butylamine ether, such as 2-methoxy ethylamine.
  • FIG. 1 is a schematic diagram illustrating a first step of a process to produce polyisobutylene-polyurethane according to some embodiments of this disclosure.
  • a polymeric material including PIB-PUR according to embodiments of this disclosure can be made by mixing soft segment components 10 , including polyisobutylene diol 12 and optional polyether diol 14 (PTMO is illustrated), and hard segment component 16 , including a diisocyanate 18 (MDI is illustrated), together and heating the mixture to an elevated temperature in the presence of a catalyst 20 to form a prepolymer 22 .
  • soft segment components 10 including polyisobutylene diol 12 and optional polyether diol 14 (PTMO is illustrated)
  • PTMO polyether diol 14
  • MDI diisocyanate 18
  • An elevated temperature is any temperature above room temperature, such as 30° C., 40° C., 50° C., 60° C., 70° C., 80° C., 90° C., or 100° C., or any temperature between any of the preceding temperatures.
  • the catalyst can be any suitable catalyst, such as, an organometallic catalyst, for example, tin(II) 2-ethylhexanoate (stannous octoate), or a tertiary amine catalyst, for example, 2,6-dimethylpyridine, 1-cyclohexyl-N,N-dimethylmethanamine, N,N,N′,N′,N′′-pentamethyldiethylenetriamine, or 4-methylmorpholine, 1-methylimidazole.
  • organometallic catalyst for example, tin(II) 2-ethylhexanoate (stannous octoate)
  • a tertiary amine catalyst for example, 2,6-dimethylpyridine, 1-
  • the second step is shown in FIG. 2 .
  • a chain extender 24 (BDO is illustrated) is reacted at an elevated temperature with the prepolymer 22 , along with the mono-functional amine 26 (butylamine is illustrated) in the presence of the catalyst 20 to form a PIB-PUR 28 .
  • the mono-functional amine 26 caps the ends of the PIB-PUR 28 , reacting with the diisocyanate 18 to prevent further chain extension.
  • the mono-functional amine 26 may also react with excess diisocyanate 18 and reduce unwanted side reactions.
  • the mono-functional amine 26 may be added to the prepolymer 22 at the same time as the chain extender 24 .
  • the mono-functional amine 26 may be added after the chain extender 24 has at least partially reacted with the prepolymer 22 to form a polymer. In some embodiments, the mono-functional amine 26 may be added to the prepolymer 22 at the same time as the chain extender 24 and after the chain extender 24 has at least partially reacted with the prepolymer 22 to form a polymer.
  • the diisocyanate 18 can be in stoichiometric excess with respect to the polyisobutylene diol 12 , the optional polyether diol 14 , and the chain extender 24 .
  • the diisocyanate 18 may be in excess to account for diisocyanate lost to reactions with residual water.
  • the diisocyanate 18 is in excess with respect to the polyisobutylene diol 12 , the optional polyether 14 , and the chain extender 24 by as little as 0.5 mole percent (mol %), 1 mol % 1.5 mol %, or 2 mol %, or as much as 2.5 mol %, 3 mol %, 4 mol %, or 5 mol %, or any value between any two of the preceding values.
  • the diisocyanate 18 is in excess with respect to the polyisobutylene diol 12 , the optional polyether 14 , and the chain extender 24 by from 0.5 mol % to 5 mol %, 1 mol % to 4 mol %, 1.5 mol % to 3 mol %, 2 mol % to 2.5 mol %, or 0.5 mol % to 2.5 mol %.
  • the mono-functional amine 26 can be added in at least equimolar amounts with respect to the diisocyanate 18 . In some embodiments, an excess of the mono-functional amine 26 can be added. If necessary, some of the excess mono-functional amine 26 can be removed by heating above the boiling point of the mono-functional amine 26 . For example, excess butylamine can be removed by heating above about 78° C., the boiling point of butylamine.
  • the PIB-PUR 28 illustrated in FIG. 2 is a polymeric material including at least soft segments including a residue of the polyisobutylene diol 12 , hard segments including at least residue of the diisocyanate 18 , and end groups bonded to some of the diisocyanate residue by a urea bond.
  • the end groups are a residue of the mono-functional amine 26 .
  • the hard segments of the embodiment shown in FIG. 2 further include a residue of the chain extender 24 .
  • the soft segments of the embodiment shown in FIG. 2 also further include a residue of the polyether diol 14 .
  • the soft segments can alternatively or additionally include a residue of a polycarbonate diol and/or a polyester diol.
  • FIG. 3 is a schematic diagram illustrating another process to produce polyisobutylene-polyurethane according to some embodiments of this disclosure.
  • the mono-functional amine 26 (butylamine is shown) is added after the polymerization reaction is at least substantially complete.
  • the polymerization reaction is at least substantially complete when there is no noticeable increase in the viscosity of the polyisobutylene-polyurethane over a period of several hours.
  • FIG. 3 shows a PIB-PUR chain 30 and a diisocyanate residue 32 bonded to a urethane linkage of the PIB-PUR 30 to form an allophanate 34 .
  • the PIB-PUR 30 may have been produced and end-capped with a mono-functional amine as for PIB-PUR 28 described above. In other embodiments, the PIB-PUR 30 may not have been end-capped with a mono-functional amine when initially synthesized.
  • the diisocyanate residue 32 may be a result of the excess of diisocyanate used to make the PIB-PUR 30 as described above.
  • the diisocyanate residue 32 also bonds with other hard or soft segment components, including other chains of the PIB-PUR 30 (not shown), thus cross-linking the other hard or soft segment components to the PIB-PUR 30 , increasing the molecular weight of the PIB-PUR 30 , and eventually gelling the PIB-PUR 30 as described above.
  • These side reactions can form the allophanate 34 .
  • Other side reactions can form other cross-linking structures, such as a biuret (not shown).
  • the allophanate 34 is a reversible bond. As noted above, it has been found that the addition of the mono-functional amine 26 , even after the PIB-PUR 30 has gelled, reverses the gelling of the PIB-PUR 30 and reduces its molecular weight. Without wishing to be bound by any theory, it is believed that the steric hindrance associated with the allophanate 34 weakens the bond, resulting in the reversible bond shown in FIG. 3 . It is believed that the diisocyanate residue 32 bonds preferentially with the mono-functional amine 26 , tying up the diisocyanate residue 32 in a more stable alkyl amine 36 (a butyl amine shown), as shown in FIG. 3 .
  • Tying up the diisocyanate reside 32 may prevent reformation of the allophanate 34 and reduce the cross-linking of the other hard or soft segment components to the PIB-PUR 30 , breaking down the gelation of the PIB-PUR 30 and reducing the molecular weight of the PIB-PUR 30 .
  • the molecular weight of the PIB-PUR 30 may be reduced to an initial molecular weight of a linear chain of PIB-PUR 30 .
  • the amine termination of the mono-functional amine 26 is believed to be well suited to this application, in contrast to, for example, a similarly-structured mono-functional alcohol. It has been found that while the mono-functional amine 26 is effective in reversing gelation of the PIB-PUR 30 , a similarly-structured mono-functional alcohol is not effective.
  • the PIB-PUR 26 or PIB-PUR 30 can be incorporated into medical devices which can be implanted or inserted into the body of a patient.
  • Example medical devices may include, without limitation, vascular grafts, electrical leads, catheters, leadless cardiac pacemakers (LCP), pelvic floor repair support devices, shock coil coverings, covered stents, urethral stents, internal feeding tubes/balloons, structural heart applications including valve leaflets, suture sleeves, breast implants, ophthalmic applications including intraocular lenses and glaucoma tubes, and spinal disc repair.
  • Example electrical leads may include, without limitation, implantable electrical stimulation or diagnostic systems including neurostimulation systems such as spinal cord stimulation (SCS) systems, deep brain stimulation (DBS) systems, peripheral nerve stimulation (PNS) systems, gastric nerve stimulation systems, cochlear implant systems, and retinal implant systems, among others, and cardiac systems including implantable cardiac rhythm management (CRM) systems, implantable cardioverter-defibrillators (ICD's), and cardiac resynchronization and defibrillation (CRDT) devices, among others.
  • neurostimulation systems such as spinal cord stimulation (SCS) systems, deep brain stimulation (DBS) systems, peripheral nerve stimulation (PNS) systems, gastric nerve stimulation systems, cochlear implant systems, and retinal implant systems, among others
  • cardiac systems including implantable cardiac rhythm management (CRM) systems, implantable cardioverter-defibrillators (ICD's), and cardiac resynchronization and defibrillation (CRDT) devices, among others.
  • CCM implantable cardiac rhythm management
  • Polyisobutylene-polyurethane block copolymer including soft segments including a polyisobutylene diol residue and hard segments including a diisocyanate residue was prepared as follows. In a 1 liter resin kettle, 106 grams of telechelic polyisobutylene diol formed from by carbocationic polymerization beginning with 5-feat-butyl-1,3-bis(1-methoxy-1-methylethyl)benzene, 72 grams of 4′-methylenediphenyl diisocyanate (MDI), and 56 grams of polytetramethylene oxide diol were dissolved in 545 grams of 2,6-dimethylpyridine.
  • MDI 4′-methylenediphenyl diisocyanate
  • the 1 liter resin kettle was equipped with overhead mechanical stirring and was purged with dry nitrogen gas.
  • the polyisobutylene diol had a number average molecular weight (Mn) of 1905 grams/mole and the polytetramethylene oxide diol had a Mn of 1000 grams/mole.
  • the solution was stirred by the overhead mechanical stirrer under the flow of nitrogen gas at a temperature of 60 degrees Celsius while the reagents reacted for 2 hours. After the 2 hours, 16 grams of freshly distilled 1,4-butanediol was added to the solution by dropwise addition and the solution maintained at a temperature of 70 degrees Celsius while the reaction continued for an additional 2 hours. After the additional 2 hours, the solution was highly viscous solution containing the PIB-PUR.
  • the PIB-PUR was stored at room temperature in a sealed container. After 15 days, the PIB-PUR was characterized by gel permeation chromatography using a multi angle light scattering detector (GPC-MALLS) to determine the number average molecular weight (Mn) and the weight average molecular weight (Mw). The PIB-PUR was recharacterized after 63 days and 98 days. The results are shown in Table 1 below. As shown in Table 1 the molecular weight increased, particularly between 64 and 98 days. At 98 days, the PIB-PUR was observed to have gelled. The gelled FIB-FUR was found to be predominantly insoluble in either 2,6-dimethylpyridine or THF, indicating that chemical cross-linking of the PIB-PUR had occurred (the molecular weight was determined from a soluble fraction).
  • GPC-MALLS multi angle light scattering detector
  • the gelled PIB-PUR was treated with butylamine in excess equimolar concentration to the MDI by adding 2,6-dimethylpyridine and 0.5 g of butylamine to 1 g of the gelled PIB-PUR, and then shaking on a shaker table at 225 rpm at 30° C. for about 12 hours.
  • the treated PIB-PUR became a viscous liquid again indicating that whatever chemical cross-linking had taken place appeared to have been reversed with the addition of the butylamine.
  • the treated PIB-PUR solution was recharacterized after 24 hours and after 25 days. The results are also shown in Table 1. As shown in Table 1, the molecular weight of the treated PIB-PUR decreased significantly with the addition of the butylamine.
  • Polyisobutylene-polyurethane block copolymer including soft segments including a polyisobutylene diol residue and hard segments including a diisocyanate residue was prepared as follows. In a 1 liter resin kettle, 105 grams of telechelic polyisobutylene diol formed from by carbocationic polymerization beginning with 5-tert-butyl-1,3-bis(1-methoxy-1-methylethyl)benzene, 72 grams of 4′-methylenediphenyl diisocyanate (MDI), and 57 grams of polytetramethylene oxide diol were dissolved in 546 grams of 2,6-dimethylpyridine.
  • telechelic polyisobutylene diol formed from by carbocationic polymerization beginning with 5-tert-butyl-1,3-bis(1-methoxy-1-methylethyl)benzene
  • MDI 4′-methylenediphenyl diisocyanate
  • the 1 liter resin kettle was equipped with overhead mechanical stirring and was purged with dry nitrogen gas.
  • the polyisobutylene diol had a number average molecular weight (Mn) of 1905 grams/mole and the polytetramethylene oxide diol had a Mn of 1000 grams/mole.
  • the solution was stirred by the overhead mechanical stirrer under the flow of nitrogen gas at a temperature of 60 degrees Celsius while the reagents reacted for 2 hours. After the 2 hours, 16 grams of freshly distilled 1,4-butanediol was added to the solution by dropwise addition and the solution maintained at a temperature of 70 degrees Celsius while the reaction continued for an additional 2 hours. After the additional 2 hours, the solution was highly viscous solution containing the PIB-PUR.
  • the PIB-PUR was stored at room temperature in a sealed container.
  • the PIB-PUR was characterized after 24 days by gel permeation chromatography using a multi angle light scattering detector (GPC-MALLS) to determine the number average molecular weight (Mn) and the weight average molecular weight (Mw). The results are shown in Table 2 below.
  • GPC-MALLS multi angle light scattering detector
  • the PIB-PUR was treated with butylamine in at least equimolar concentration to the MDI by adding 2,6-dimethylpyridine and 0.08 g of butylamine to 1 g of the PIB-PUR, and then shaken on a shaker table at 225 rpm at 30° C. for about 12 hours.
  • the treated PIB-PUR solution was stored at room temperature in a sealed container and recharacterized after 24 hours.
  • Table 2 As shown in Table 2, the molecular weight of the treated PIB-PUR decreased significantly with the addition of the butylamine suggesting that at least some of the chemical cross-linking that had taken place over 24 days appeared to have been reversed with the addition of the butylamine.
  • a dynamic viscosity was measured for various concentrations of the PIB-PUR of Example 2 in 2,6-dimethylpyridine before treatment 40 and 24 hours after treatment 42 with the butylamine.
  • Three PIB-PUR solutions of various concentrations were prepared for each of the before treatment 40 and after treatment 42 by adding appropriate amounts of 2,6-dimethylpyridine. The results are shown in FIG. 4 .
  • the dynamic viscosity dropped significantly with the addition of the butylamine, again suggesting that at least some of the chemical cross-linking that had taken place over 24 days appeared to have been reversed with the addition of the butylamine.
  • Polyisobutylene-polyurethane block copolymer including soft segments including a polyisobutylene diol residue and hard segments including a diisocyanate residue was prepared as follows. In a 1 liter resin kettle 13 grams of telechelic polyisobutylene diol formed from by carbocationic polymerization beginning with 5-tert-butyl-1,3-bis(1-methoxy-1-methylethyl)benzene, 9 grams of 4′-methylenediphenyl diisocyanate (MDI), and 7 grams of polytetramethylene oxide diol were dissolved in 8 grams of 2,6-dimethylpyridine.
  • MDI 4′-methylenediphenyl diisocyanate
  • the 1 liter resin kettle was equipped with overhead mechanical stirring and was purged with dry nitrogen gas.
  • the polyisobutylene diol had a number average molecular weight (Mn) of 1905 grams/mole and the polytetramethylene oxide diol had a Mn of 1000 grams/mole.
  • the solution was stirred by the overhead mechanical stirrer under the flow of nitrogen gas at a temperature of 60 degrees Celsius while the reagents reacted for 2 hours. After the 2 hours, 2 grams of freshly distilled 1,4-butanediol was added to the solution by dropwise addition and the solution maintained at a temperature of 70 degrees Celsius while the reaction continued for an additional 2 hours. After the additional 2 hours, the solution was highly viscous solution containing the PIB-PUR.
  • the PIB-PUR was stored at room temperature in a sealed container.
  • the PIB-PUR was characterized after 21 days by gel permeation chromatography using a multi angle light scattering detector (GPC-MALLS) to determine the number average molecular weight (Mn) and the weight average molecular weight (Mw). The results are shown in Table 3 below.
  • the PIB-PUR was treated with butylamine in at least equimolar concentration to the MDI by adding 2,6-dimethylpyridine and 0.08 g of butylamine to 1 g of the PIB-PUR, and then shaken on a shaker table at 225 rpm at 30° C. for about 12 hours.
  • the treated PIB-PUR solution was stored at room temperature in a sealed container and recharacterized after 24 hours and after 17 days.
  • Table 3 As shown in Table 3, the molecular weight of the treated PIB-PUR decreased significantly with the addition of the butylamine suggesting that at least some of the chemical cross-linking that had taken place over 21 days appeared to have been reversed with the addition of the butylamine. As further shown in Table 3, the cross-links did not reappear over an additional 17 days of storage.
  • a dynamic viscosity was measured for various concentrations of the FIB-FUR of Example 2 in 2,6-dimethylpyridine before treatment 44 and 24 hours after treatment 46 with the butylamine.
  • Three PIB-PUR solutions of various concentrations were prepared for each of the before treatment 40 and after treatment 42 by adding appropriate amounts of 2,6-dimethylpyridine. The results are shown in FIG. 4 .
  • the dynamic viscosity dropped significantly with the addition of the butylamine, again suggesting that at least some of the chemical cross-linking that had taken place over 24 days appeared to have been reversed with the addition of the butylamine.

Abstract

A polymeric material includes a polyisobutylene-polyurethane block copolymer. The polyisobutylene-polyurethane block copolymer includes soft segments, hard segments, and end groups. The soft segments include a polyisobutylene diol residue. The hard segments include a diisocyanate residue. The end groups are bonded by urea bonds to a portion of the diisocyanate residue. The end groups include a residue of a mono-functional amine.

Description

    CROSS-REFERENCE TO RELATED APPLICATION
  • The present application is a continuation of and claims priority to U.S. patent application Ser. No. 16/248,498, filed Jan. 15, 2019 and claims priority to U.S. Provisional Application No. 62/618,262, filed Jan. 17, 2018, both of which are herein incorporated by reference in their entirety.
  • TECHNICAL FIELD
  • The present disclosure relates to polymeric materials. More specifically, the disclosure relates to polyisobutylene-polyurethane block copolymers, methods for making polyisobutylene-polyurethane block copolymers, and medical devices containing polyisobutylene-polyurethane block copolymers
  • BACKGROUND
  • Polymeric materials are widely used in the field of medical devices. For example, polymeric materials such as silicone rubber, polyurethane, and fluoropolymers are used as coating and/or insulating materials for medical leads, stents, catheters, and other devices.
  • Block copolymers are polymeric materials made of alternating sections of polymerized monomers. Polyisobutylene-polyurethane block copolymers are polymeric materials with many unique physical and mechanical properties. Exemplary properties, which may be particularly desirable in the field of medical devices, include thermal stability, chemical resistance, biocompatibility, and gas impermeability, among others.
  • Incorporating polymeric materials into implantable medical devices may be done by a variety of methods, depending on the specific application. In some applications, for example, for implantable lead bodies, the polymeric material may be extruded at a temperature sufficient to cause the block copolymer to flow, but not high enough to cause the polymeric material to break down. That is, the material that forms the lead after the extrusion and cooling has largely the same structure as the original polymeric material.
  • In other applications, it may be desirable to employ solvent-based processing to incorporate a polymeric material into an implantable medical device. Solvent-based processing includes electrospraying, electrospinning, spray coating, dip coating, and force spinning. Essential to all solvent-based processing of polymeric materials is the ability to bring the polymeric material into solution while retaining the basic structure of the polymeric material.
  • SUMMARY
  • Example 1 is a polymeric material including a polyisobutylene-polyurethane block copolymer. The polyisobutylene-polyurethane block copolymer includes soft segments, hard segments, and end groups. The soft segments include a polyisobutylene diol residue. The hard segments include a diisocyanate residue. The end groups are bonded by urea bonds to a portion of the diisocyanate residue. The end groups include a residue of a mono-functional amine.
  • Example 2 is the polymeric material of Example 1, wherein the mono-functional amine is a primary amine or a secondary amine.
  • Example 3 is the polymeric material of either of Examples 1 or 2, wherein the mono-functional amine includes a C3 to C30 aliphatic chain.
  • Example 4 is the polymeric material of any of Examples 1-3, wherein the mono-functional amine is butylamine.
  • Example 5 is the polymeric material of any of Examples 1-4, wherein the soft segments are present in the copolymer in an amount of about 40% to about 70% by weight of the copolymer, and the hard segments are present in the copolymer in an amount of about 30% to about 60% by weight of the copolymer.
  • Example 6 is the polymeric material of any of Examples 1-5, wherein the diisocyanate residue includes 4,4′-methylene diphenyl diisocyanate residue.
  • Example 7 is the polymeric material of any of Examples 1-6, wherein the hard segments further include a chain extender residue.
  • Example 8 is the polymeric material of Example 7, wherein the chain extender residue is 1,4-butanediol residue.
  • Example 9 is the polymeric material of any of Examples 1-8, wherein the soft segments further include at least one of a polyether diol residue, a polyester diol residue, and a polycarbonate diol residue.
  • Example 10 is a medical device including the polymeric material of any of Examples 1-9.
  • Example 11 is a method of making a polymeric material. The method includes heating a mixture of soft segment components and hard segment components to an elevated temperature to form a prepolymer, reacting a chain extender with the prepolymer to form a polymer, and reacting an end capping agent with at least one of: the prepolymer and the polymer to form the polymeric material. The soft segment components include a polyisobutylene diol. The hard segment components include a diisocyanate. The end capping agent includes a mono-functional amine.
  • Example 12 is the method of Example 11, wherein the mono-functional amine is a primary amine or a secondary amine.
  • Example 13 is the method of either of Examples 11 or 12, wherein the mono-functional amine includes a C3 to C30 aliphatic chain.
  • Example 14 is the method of any of Examples 11-13, wherein the mono-functional amine is butylamine.
  • Example 15 is the method of any of Examples 11-14, wherein the diisocyanate is in stoichiometric excess with respect to the polyisobutylene diol and the chain extender, and the mono-functional amine is an at least equimolar amount with respect to the diisocyanate.
  • Example 16 is a polymeric material including a polyisobutylene-polyurethane block copolymer. The polyisobutylene-polyurethane block copolymer includes soft segments, hard segments, and end groups. The soft segments include a polyisobutylene diol residue. The hard segments include a diisocyanate residue. The end groups are bonded by urea bonds to a portion of the diisocyanate residue. The end groups include a residue of a mono-functional amine including a C3 to C30 aliphatic chain.
  • Example 17 is the polymeric material of Example 16, wherein the mono-functional amine is a primary amine or a secondary amine.
  • Example 18 is the polymeric material of Example of either of Examples 16 or 17, wherein the mono-functional amine is butylamine.
  • Example 19 is the polymeric material of any of Examples 16-18, wherein the soft segments are present in the copolymer in an amount of about 40% to about 70% by weight of the copolymer, and the hard segments are present in the copolymer in an amount of about 30% to about 60% by weight of the copolymer.
  • Example 20 is the polymeric material of any of Examples 16-19, wherein the diisocyanate residue includes 4,4′-methylene diphenyl diisocyanate residue.
  • Example 21 is the polymeric material of any of Examples 16-19, wherein the hard segments further include a chain extender residue.
  • Example 22 is the polymeric material of Example 21, wherein the chain extender residue is 1,4-butanediol residue.
  • Example 23 is the polymeric material of any of Examples 16-22, wherein the soft segments further include at least one of: a polyether diol residue, a polyester diol residue, and a polycarbonate dial residue.
  • Example 24 a medical device including a polymeric material. The polymeric material includes a polyisobutylene-polyurethane block copolymer. The polyisobutylene-polyurethane block copolymer includes soft segments, hard segments, and end groups. The soft segments include a polyisobutylene diol residue. The hard segments include a diisocyanate residue. The end groups are bonded by urea bonds to a portion of the diisocyanate residue. The end groups include a residue of a mono-functional amine including a C3 to C30 aliphatic chain.
  • Example 25 is the medical device of Example 24, wherein the mono-functional amine is a primary amine or a secondary amine.
  • Example 26 is the medical device of either of Examples 24 or 25, wherein the mono-functional amine is butylamine.
  • Example 27 is the medical device of any of Examples 24-26, wherein the soft segments are present in the copolymer in an amount of about 40% to about 70% by weight of the copolymer, and the hard segments are present in the copolymer in an amount of about 30% to about 60% by weight of the copolymer.
  • Example 28 is the medical device of any of Examples 24-27, wherein the diisocyanate residue includes 4,4′-methylene diphenyl diisocyanate residue.
  • Example 29 is a method of making a polymeric material. The method includes heating a mixture of soft segment components and hard segment components to an elevated temperature to form a prepolymer, reacting a chain extender with the prepolymer to form a polymer, and reacting an end capping agent with at least one of: the prepolymer and the polymer to form the polymeric material. The soft segment components include a polyisobutylene diol. The hard segment components include a diisocyanate. The end capping agent includes a mono-functional amine including a C3 to C30 aliphatic chain.
  • Example 30 is the method of Example 29, wherein the mono-functional amine is a primary amine or a secondary amine.
  • Example 31 is the method of either of Examples 29 or 30, wherein the mono-functional amine is butylamine.
  • Example 32 is the method of any of Examples 29-31, wherein the diisocyanate is in stoichiometric excess with respect to the polyisobutylene diol and the chain extender, and the mono-functional amine is an at least equimolar amount with respect to the diisocyanate.
  • Example 33 is the method of any of Examples 29-32, wherein heating the mixture of the soft segment components and the hard segment components to an elevated temperature and reacting the chain extender with the heated mixture are in the presence of a tertiary amine catalyst.
  • Example 34 is the method of Example 29, wherein the diisocyanate includes 4,4′-methylene diphenyl diisocyanate.
  • Example 35 is the method of any of Examples 29-34, wherein the soft segment components further include a polytetramethylene oxide diol, the diisocyanate is in stoichiometric excess with respect to the polyisobutylene diol, the chain extender, and the polytetramethylene oxide diol, and the mono-functional amine is an at least equimolar amount with respect to the diisocyanate.
  • While multiple examples are disclosed, still other examples in accordance with this disclosure will become apparent to those skilled in the art from the following detailed description, which shows and describes illustrative embodiments. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not restrictive.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a schematic diagram illustrating a first step of a process to produce polyisobutylene-polyurethane according to some embodiments of this disclosure.
  • FIG. 2 is a schematic diagram illustrating a second step of a process to produce polyisobutylene-polyurethane according to some embodiments of this disclosure.
  • FIG. 3 is a schematic diagram illustrating another process to produce polyisobutylene-polyurethane according to some embodiments of this disclosure.
  • FIG. 4 is a plot of dynamic viscosity as a function of concentration for polyisobutylene-polyurethane solutions according to some embodiments of this disclosure.
  • While this disclosure is amenable to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and are described in detail below. The intention, however, is not to limit the disclosure to the particular embodiments described. On the contrary, this disclosure is intended to cover all modifications, equivalents, and alternatives falling within the scope of the disclosure as defined by the appended claims.
  • DETAILED DESCRIPTION
  • In accordance with various aspects of the disclosure, polyisobutylene-polyurethane block copolymers (also referred to herein collectively as “PIB-PUR”) and methods for making the same are disclosed. Medical devices that can be implantable or insertable into the body of a patient and that comprise a polyisobutylene urethane copolymer are also disclosed. PIB-PUR is a thermoplastic polyurethane (TPUs) that contains hard and soft segments. PIB-PUR is useful in a number of applications, including in medical devices used for insertion or implantation into a patient because they are hydrolytically stable and have good oxidative stability.
  • Polyurethanes are a family of copolymers that are synthesized from polyfunctional isocyanates (e.g., diisocyanates, including both aliphatic and aromatic diisocyanates) and polyols (e.g., macroglycols). Commonly employed macroglycols include polyester diols, polyether diols and polycarbonate diols. The macroglycols can form polymeric segments of the polyurethane. Aliphatic or aromatic diols may also be employed as chain extenders, for example, to impart improved physical properties to the polyurethane.
  • In some embodiments, the polyisobutylene urethane copolymer includes one or more polyisobutylene segments, one or more segments that includes one or more diisocyanate residues, optionally one or more additional polymeric segments (other than polyisobutylene segments), and optionally one or more chain extenders.
  • As used herein, a “polymeric segment” or “segment” is a portion of a polymer. The polyisobutylene segments of the polyisobutylene urethane copolymers are generally considered to constitute soft segments, while the segments containing the diisocyanate residues are generally considered to constitute hard segments. The additional polymeric segments may include soft or hard polymeric segments. As used herein, soft and hard segments are relative terms to describe the properties of polymer materials containing such segments. Without limiting the foregoing, a soft segment may display a glass transition temperature (Tg) that is below body temperature, more typically from 35° C. to 20° C. to 0° C. to −25° C. to −50° C. or below. A hard segment may display a Tg that is above body temperature, more typically from 40° C. to 50° C. to 75° C. to 100° C. or above. Tg can be measured by differential scanning calorimetry (DSC), dynamic mechanical analysis (DMA) and/or thermomechanical analysis (TMA).
  • The weight ratio of soft segments to hard segments in the polyisobutylene urethane copolymers of the various embodiments can be varied to achieve a wide range of physical and mechanical properties, and to achieve an array of desirable functional performance. For example, the weight ratio of soft segments to hard segments in the polymer can be varied from 99:1 to 95:5 to 90:10 to 75:25 to 50:50 to 25:75 to 10:90 to 5:95 to 1:99, more particularly from 95:5 to 90:10 to 80:20 to 70:30 to 65:35 to 60:40 to 50:50, and even more particularly, from about 80:20 to about 50:50. In some embodiments, the soft segment components can be about 40% to about 70% by weight of the copolymer, and the hard segment components can be about 30% to about 60% by weight of the copolymer.
  • In some embodiments, the copolymer may include polyisobutylene in an amount of about 60% to about 100% by weight of the soft segments and a polyether, a polyester, or a polycarbonate in an amount of about 0% to about 40% by weight of the soft segments. For example, the copolymer may include soft segments in an amount of about 40% to about 70% by weight of the copolymer, of which polyisobutylene is present in an amount of about 60% to about 100% by weight of the soft segments and polyether is present in an amount of about 0% to about 40% by weight of the soft segments. In another embodiment, the copolymer may include soft segments in an amount of about 40% to about 70% by weight of the copolymer, of which polyisobutylene (e.g., a polyisobutylene diol residue) is present in an amount of about 70% to about 95% by weight of the soft segments and a polyether (e.g., polytetramethylene oxide diol residue) is present in an amount of about 5% to about 40% by weight of the soft segments.
  • Diisocyanates for use in forming PIB-PUR of the various embodiments include aromatic and non-aromatic (e.g., aliphatic) diisocyanates. Aromatic diisocyanates may be selected from suitable members of the following, among others: 4,4′-methylenediphenyl diisocyanate (MDI), 2,4′-methylenediphenyl diisocyanate (2,4-MDI), 2,4- and/or 2,6-toluene diisocyanate (TDI), 1,5-naphthalene diisocyanate (NDI), para-phenylene diisocyanate, 3,3′-tolidene-4,4′-diisocyanate and 3,3′-dimethyl-diphenylmethane-4,4′-diisocyanate. Non-aromatic diisocyanates may be selected from suitable members of the following, among others: 1,6-hexamethylene diisocyanate (HDI), 4,4′-dicyclohexylmethane diisocyanate (H12-MDI), 3-isocyanatomethyl-3,5,5-trimethylcyclohexyl isocyanate (isophorone diisocyanate or IPDI), cyclohexyl diisocyanate, and 2,2,4-trimethyl-1,6-hexamethylene diisocyanate (TMDI).
  • In some embodiments, a polyether diol such as polytetramethylene oxide diol (PTMO diol), polyhexametheylene oxide diol (PHMO diol), polyoctamethylene oxide diol or polydecamethylene oxide diol, can be combined with a polyisobutylene diol and diisocyanate to form a polyisobutylene polyurethane copolymer. In some embodiments, PIB-PUR may have a generally uniform distribution of polyurethane hard segments, polyisobutylene segments and polyether segments to achieve favorable micro-phase separation in the polymer. In some embodiments, polyether segments may improve key mechanical properties such as Shore hardness, tensile strength, tensile modulus, flexural modulus, elongation tear strength, flex fatigue, tensile creep, and/or abrasion performance, among others.
  • The polyisobutylene diol may be a telechelic polyisobutylene diol formed from by carbocationic polymerization beginning with a difunctional initiator compound, such as 5-tert-butyl-1,3-bis(1-methoxy-1-methylethyl)benzene (hindered dicumyl ether).
  • PIB-PUR in accordance with the various embodiments may further include one or more optional chain extender residues. Chain extenders can increase the hard segment length, which can in turn results in a copolymer with a higher tensile modulus, lower elongation at break and/or increased strength.
  • Chain extenders can be formed from aliphatic or aromatic diols, in which case a urethane bond is formed upon reaction with an isocyanate group. Chain extenders may be selected from suitable members of the following, among others: 1,4 cyclohexanedimethanol, alpha,omega-alkane diols such as ethylene glycol (1,2-ethane diol), 1,4-butanediol (BDO), and 1,6-hexanediol. Chain extenders may be also selected from suitable members of, among others, short chain diol polymers (e.g., alpha,omega-dihydroxy-terminated polymers having a molecular weight less than or equal to 1000) based on hard and soft polymeric segments (more typically soft polymeric segments) such as those described above, including short chain polyisobutylene diols, short chain polyether polyols such as polytetramethylene oxide diols, short chain polysiloxane diols such as polydimethylsiloxane dials, short chain polycarbonate diols such as polyhexamethylene carbonate diols, short chain poly(fluorinated ether) diols, short chain polyester dials, short chain polyacrylate dials, short chain polymethacrylate dials, and short chain polyvinyl aromatic) dials. Chain extenders may also be selected form suitable glycols, such as propylene glycol, dipropylene glycol, and tripropylene glycol.
  • As noted above, it may be desirable to employ solvent-based processing to incorporate a polymeric material, such as PIB-PUR, into an implantable medical device. In some embodiments, the PIB-PUR may be synthesized and stored for a period of time until it is incorporated into the solvent processing. For example, the FIB-PUR may be stored for a period of days, weeks or months. For solvent processing, the PIB-PUR is dissolved in a solvent, such as, for example, 2,6-dimethylpyridine or tetrahydrofuran (THF), to obtain a desired concentration and/or viscosity of the resulting PIB-PUR solution. The PIB-PUR solution can then be deposited onto a substrate, such as a medical device, by electrospraying, electrospinning, spray coating, dip coating, or force spinning.
  • It has been found that as PIB-PUR is stored for an extended period of time, on the order of weeks and months, the molecular weight (both the weight average molecular weight (Mw) and the number average molecular weight (Mn)) of the PIB-PUR can increase during the storage period. In some cases, the stored PIB-PUR forms a gel. Such gels are that is no longer easily soluble in 2,6-dimethylpyridine or THF and thus, no longer suitable for solvent-based processing.
  • It has been found that, in some embodiments, an end-capping agent that is a mono-functional amine can mitigate the increase in molecular weight due to extended storage time. In addition, it has been found that, in some embodiments, the addition of such an end capping agent to PIB-PUR that has been stored for an extended period of time can reverse the increase in molecular weight of the PIB-PUR. Further, it has been found that the addition of such an end capping agent to PIB-PUR even after is has gelled and is no longer soluble in 2,6-dimethylpyridine or THF can break down the cross-links in the gel so that the PIB-PUR is soluble in 2,6-dimethylpyridine or THF. A gel is defined as a substantially dilute cross-linked system which exhibits no flow when in a steady-state.
  • The mono-functional amine can include a C3 to C30 aliphatic chain that can be straight or branched, saturated or unsaturated, a primary amine or a secondary amine. For example, in some embodiments, the mono-functional amine can be a butylamine or a butylamine ether, such as 2-methoxy ethylamine.
  • FIG. 1 is a schematic diagram illustrating a first step of a process to produce polyisobutylene-polyurethane according to some embodiments of this disclosure. A polymeric material including PIB-PUR according to embodiments of this disclosure can be made by mixing soft segment components 10, including polyisobutylene diol 12 and optional polyether diol 14 (PTMO is illustrated), and hard segment component 16, including a diisocyanate 18 (MDI is illustrated), together and heating the mixture to an elevated temperature in the presence of a catalyst 20 to form a prepolymer 22.
  • An elevated temperature is any temperature above room temperature, such as 30° C., 40° C., 50° C., 60° C., 70° C., 80° C., 90° C., or 100° C., or any temperature between any of the preceding temperatures. The catalyst can be any suitable catalyst, such as, an organometallic catalyst, for example, tin(II) 2-ethylhexanoate (stannous octoate), or a tertiary amine catalyst, for example, 2,6-dimethylpyridine, 1-cyclohexyl-N,N-dimethylmethanamine, N,N,N′,N′,N″-pentamethyldiethylenetriamine, or 4-methylmorpholine, 1-methylimidazole.
  • The second step is shown in FIG. 2 . A chain extender 24 (BDO is illustrated) is reacted at an elevated temperature with the prepolymer 22, along with the mono-functional amine 26 (butylamine is illustrated) in the presence of the catalyst 20 to form a PIB-PUR 28. As shown in FIG. 2 , the mono-functional amine 26 caps the ends of the PIB-PUR 28, reacting with the diisocyanate 18 to prevent further chain extension. The mono-functional amine 26 may also react with excess diisocyanate 18 and reduce unwanted side reactions. In some embodiments, the mono-functional amine 26 may be added to the prepolymer 22 at the same time as the chain extender 24. In other embodiments, the mono-functional amine 26 may be added after the chain extender 24 has at least partially reacted with the prepolymer 22 to form a polymer. In some embodiments, the mono-functional amine 26 may be added to the prepolymer 22 at the same time as the chain extender 24 and after the chain extender 24 has at least partially reacted with the prepolymer 22 to form a polymer.
  • The diisocyanate 18 can be in stoichiometric excess with respect to the polyisobutylene diol 12, the optional polyether diol 14, and the chain extender 24. The diisocyanate 18 may be in excess to account for diisocyanate lost to reactions with residual water. For example, in some embodiments, the diisocyanate 18 is in excess with respect to the polyisobutylene diol 12, the optional polyether 14, and the chain extender 24 by as little as 0.5 mole percent (mol %), 1 mol % 1.5 mol %, or 2 mol %, or as much as 2.5 mol %, 3 mol %, 4 mol %, or 5 mol %, or any value between any two of the preceding values. For example in some embodiments, the diisocyanate 18 is in excess with respect to the polyisobutylene diol 12, the optional polyether 14, and the chain extender 24 by from 0.5 mol % to 5 mol %, 1 mol % to 4 mol %, 1.5 mol % to 3 mol %, 2 mol % to 2.5 mol %, or 0.5 mol % to 2.5 mol %.
  • In some embodiments, the mono-functional amine 26 can be added in at least equimolar amounts with respect to the diisocyanate 18. In some embodiments, an excess of the mono-functional amine 26 can be added. If necessary, some of the excess mono-functional amine 26 can be removed by heating above the boiling point of the mono-functional amine 26. For example, excess butylamine can be removed by heating above about 78° C., the boiling point of butylamine.
  • Thus, the PIB-PUR 28 illustrated in FIG. 2 is a polymeric material including at least soft segments including a residue of the polyisobutylene diol 12, hard segments including at least residue of the diisocyanate 18, and end groups bonded to some of the diisocyanate residue by a urea bond. The end groups are a residue of the mono-functional amine 26. The hard segments of the embodiment shown in FIG. 2 further include a residue of the chain extender 24. The soft segments of the embodiment shown in FIG. 2 also further include a residue of the polyether diol 14. In some embodiments, the soft segments can alternatively or additionally include a residue of a polycarbonate diol and/or a polyester diol.
  • FIG. 3 is a schematic diagram illustrating another process to produce polyisobutylene-polyurethane according to some embodiments of this disclosure. In the embodiment shown in FIG. 3 , the mono-functional amine 26 (butylamine is shown) is added after the polymerization reaction is at least substantially complete. The polymerization reaction is at least substantially complete when there is no noticeable increase in the viscosity of the polyisobutylene-polyurethane over a period of several hours. FIG. 3 shows a PIB-PUR chain 30 and a diisocyanate residue 32 bonded to a urethane linkage of the PIB-PUR 30 to form an allophanate 34. In some embodiments, the PIB-PUR 30 may have been produced and end-capped with a mono-functional amine as for PIB-PUR 28 described above. In other embodiments, the PIB-PUR 30 may not have been end-capped with a mono-functional amine when initially synthesized. The diisocyanate residue 32 may be a result of the excess of diisocyanate used to make the PIB-PUR 30 as described above.
  • Without wishing to be bound by any theory, it is believed that during storing for an extended period of time, the diisocyanate residue 32 also bonds with other hard or soft segment components, including other chains of the PIB-PUR 30 (not shown), thus cross-linking the other hard or soft segment components to the PIB-PUR 30, increasing the molecular weight of the PIB-PUR 30, and eventually gelling the PIB-PUR 30 as described above. These side reactions can form the allophanate 34. Other side reactions can form other cross-linking structures, such as a biuret (not shown).
  • The allophanate 34 is a reversible bond. As noted above, it has been found that the addition of the mono-functional amine 26, even after the PIB-PUR 30 has gelled, reverses the gelling of the PIB-PUR 30 and reduces its molecular weight. Without wishing to be bound by any theory, it is believed that the steric hindrance associated with the allophanate 34 weakens the bond, resulting in the reversible bond shown in FIG. 3 . It is believed that the diisocyanate residue 32 bonds preferentially with the mono-functional amine 26, tying up the diisocyanate residue 32 in a more stable alkyl amine 36 (a butyl amine shown), as shown in FIG. 3 . Tying up the diisocyanate reside 32 may prevent reformation of the allophanate 34 and reduce the cross-linking of the other hard or soft segment components to the PIB-PUR 30, breaking down the gelation of the PIB-PUR 30 and reducing the molecular weight of the PIB-PUR 30. In some embodiments, the molecular weight of the PIB-PUR 30 may be reduced to an initial molecular weight of a linear chain of PIB-PUR 30.
  • The amine termination of the mono-functional amine 26 is believed to be well suited to this application, in contrast to, for example, a similarly-structured mono-functional alcohol. It has been found that while the mono-functional amine 26 is effective in reversing gelation of the PIB-PUR 30, a similarly-structured mono-functional alcohol is not effective.
  • The PIB-PUR 26 or PIB-PUR 30 according to embodiments of this disclosure can be incorporated into medical devices which can be implanted or inserted into the body of a patient. Example medical devices may include, without limitation, vascular grafts, electrical leads, catheters, leadless cardiac pacemakers (LCP), pelvic floor repair support devices, shock coil coverings, covered stents, urethral stents, internal feeding tubes/balloons, structural heart applications including valve leaflets, suture sleeves, breast implants, ophthalmic applications including intraocular lenses and glaucoma tubes, and spinal disc repair. Example electrical leads may include, without limitation, implantable electrical stimulation or diagnostic systems including neurostimulation systems such as spinal cord stimulation (SCS) systems, deep brain stimulation (DBS) systems, peripheral nerve stimulation (PNS) systems, gastric nerve stimulation systems, cochlear implant systems, and retinal implant systems, among others, and cardiac systems including implantable cardiac rhythm management (CRM) systems, implantable cardioverter-defibrillators (ICD's), and cardiac resynchronization and defibrillation (CRDT) devices, among others.
  • EXAMPLES
  • The present disclosure is more particularly described in the following examples that are intended as illustrations only, since numerous modifications and variations within the scope of the present disclosure will be apparent to those of skill in the art. Unless otherwise noted, all parts, percentages, and ratios reported in the following examples are on a weight bases, and all reagents used in the examples were obtained, or are available, from the chemical suppliers described below, or may be synthesized by conventional techniques.
  • Example 1 PIB-PUR Treatment after 98 Days
  • Polyisobutylene-polyurethane block copolymer (PIB-PUR) including soft segments including a polyisobutylene diol residue and hard segments including a diisocyanate residue was prepared as follows. In a 1 liter resin kettle, 106 grams of telechelic polyisobutylene diol formed from by carbocationic polymerization beginning with 5-feat-butyl-1,3-bis(1-methoxy-1-methylethyl)benzene, 72 grams of 4′-methylenediphenyl diisocyanate (MDI), and 56 grams of polytetramethylene oxide diol were dissolved in 545 grams of 2,6-dimethylpyridine. The 1 liter resin kettle was equipped with overhead mechanical stirring and was purged with dry nitrogen gas. The polyisobutylene diol had a number average molecular weight (Mn) of 1905 grams/mole and the polytetramethylene oxide diol had a Mn of 1000 grams/mole. The solution was stirred by the overhead mechanical stirrer under the flow of nitrogen gas at a temperature of 60 degrees Celsius while the reagents reacted for 2 hours. After the 2 hours, 16 grams of freshly distilled 1,4-butanediol was added to the solution by dropwise addition and the solution maintained at a temperature of 70 degrees Celsius while the reaction continued for an additional 2 hours. After the additional 2 hours, the solution was highly viscous solution containing the PIB-PUR.
  • The PIB-PUR was stored at room temperature in a sealed container. After 15 days, the PIB-PUR was characterized by gel permeation chromatography using a multi angle light scattering detector (GPC-MALLS) to determine the number average molecular weight (Mn) and the weight average molecular weight (Mw). The PIB-PUR was recharacterized after 63 days and 98 days. The results are shown in Table 1 below. As shown in Table 1 the molecular weight increased, particularly between 64 and 98 days. At 98 days, the PIB-PUR was observed to have gelled. The gelled FIB-FUR was found to be predominantly insoluble in either 2,6-dimethylpyridine or THF, indicating that chemical cross-linking of the PIB-PUR had occurred (the molecular weight was determined from a soluble fraction).
  • The gelled PIB-PUR was treated with butylamine in excess equimolar concentration to the MDI by adding 2,6-dimethylpyridine and 0.5 g of butylamine to 1 g of the gelled PIB-PUR, and then shaking on a shaker table at 225 rpm at 30° C. for about 12 hours. The treated PIB-PUR became a viscous liquid again indicating that whatever chemical cross-linking had taken place appeared to have been reversed with the addition of the butylamine. The treated PIB-PUR solution was recharacterized after 24 hours and after 25 days. The results are also shown in Table 1. As shown in Table 1, the molecular weight of the treated PIB-PUR decreased significantly with the addition of the butylamine.
  • TABLE 1
    PIB-PUR Mn Mw
    After 15 days 128,100 286,100
    After 63 days 132,200 282,500
    After 98 days 213,100 393,100
    24 hours after 109,200 259,700
    Butylamine
    Treatment
    25 days after 89,600 217,000
    Butylamine
    Treatment
  • Example 2 PIB-PUR Treatment after 24 Days
  • Polyisobutylene-polyurethane block copolymer (PIB-PUR) including soft segments including a polyisobutylene diol residue and hard segments including a diisocyanate residue was prepared as follows. In a 1 liter resin kettle, 105 grams of telechelic polyisobutylene diol formed from by carbocationic polymerization beginning with 5-tert-butyl-1,3-bis(1-methoxy-1-methylethyl)benzene, 72 grams of 4′-methylenediphenyl diisocyanate (MDI), and 57 grams of polytetramethylene oxide diol were dissolved in 546 grams of 2,6-dimethylpyridine. The 1 liter resin kettle was equipped with overhead mechanical stirring and was purged with dry nitrogen gas. The polyisobutylene diol had a number average molecular weight (Mn) of 1905 grams/mole and the polytetramethylene oxide diol had a Mn of 1000 grams/mole. The solution was stirred by the overhead mechanical stirrer under the flow of nitrogen gas at a temperature of 60 degrees Celsius while the reagents reacted for 2 hours. After the 2 hours, 16 grams of freshly distilled 1,4-butanediol was added to the solution by dropwise addition and the solution maintained at a temperature of 70 degrees Celsius while the reaction continued for an additional 2 hours. After the additional 2 hours, the solution was highly viscous solution containing the PIB-PUR.
  • The PIB-PUR was stored at room temperature in a sealed container. The PIB-PUR was characterized after 24 days by gel permeation chromatography using a multi angle light scattering detector (GPC-MALLS) to determine the number average molecular weight (Mn) and the weight average molecular weight (Mw). The results are shown in Table 2 below.
  • The PIB-PUR was treated with butylamine in at least equimolar concentration to the MDI by adding 2,6-dimethylpyridine and 0.08 g of butylamine to 1 g of the PIB-PUR, and then shaken on a shaker table at 225 rpm at 30° C. for about 12 hours. The treated PIB-PUR solution was stored at room temperature in a sealed container and recharacterized after 24 hours. The results are also shown in Table 2. As shown in Table 2, the molecular weight of the treated PIB-PUR decreased significantly with the addition of the butylamine suggesting that at least some of the chemical cross-linking that had taken place over 24 days appeared to have been reversed with the addition of the butylamine.
  • TABLE 2
    PIB-PUR Mn Mw
    After 24 days 138,700 313,600
    24 hours after 51,330 142,500
    Butylamine
    Treatment
  • A dynamic viscosity was measured for various concentrations of the PIB-PUR of Example 2 in 2,6-dimethylpyridine before treatment 40 and 24 hours after treatment 42 with the butylamine. Three PIB-PUR solutions of various concentrations were prepared for each of the before treatment 40 and after treatment 42 by adding appropriate amounts of 2,6-dimethylpyridine. The results are shown in FIG. 4 . As shown in FIG. 4 , the dynamic viscosity dropped significantly with the addition of the butylamine, again suggesting that at least some of the chemical cross-linking that had taken place over 24 days appeared to have been reversed with the addition of the butylamine.
  • Example 3 PIB-PUR Treatment after 21 Days
  • Polyisobutylene-polyurethane block copolymer (PIB-PUR) including soft segments including a polyisobutylene diol residue and hard segments including a diisocyanate residue was prepared as follows. In a 1 liter resin kettle 13 grams of telechelic polyisobutylene diol formed from by carbocationic polymerization beginning with 5-tert-butyl-1,3-bis(1-methoxy-1-methylethyl)benzene, 9 grams of 4′-methylenediphenyl diisocyanate (MDI), and 7 grams of polytetramethylene oxide diol were dissolved in 8 grams of 2,6-dimethylpyridine. The 1 liter resin kettle was equipped with overhead mechanical stirring and was purged with dry nitrogen gas. The polyisobutylene diol had a number average molecular weight (Mn) of 1905 grams/mole and the polytetramethylene oxide diol had a Mn of 1000 grams/mole. The solution was stirred by the overhead mechanical stirrer under the flow of nitrogen gas at a temperature of 60 degrees Celsius while the reagents reacted for 2 hours. After the 2 hours, 2 grams of freshly distilled 1,4-butanediol was added to the solution by dropwise addition and the solution maintained at a temperature of 70 degrees Celsius while the reaction continued for an additional 2 hours. After the additional 2 hours, the solution was highly viscous solution containing the PIB-PUR.
  • The PIB-PUR was stored at room temperature in a sealed container. The PIB-PUR was characterized after 21 days by gel permeation chromatography using a multi angle light scattering detector (GPC-MALLS) to determine the number average molecular weight (Mn) and the weight average molecular weight (Mw). The results are shown in Table 3 below.
  • The PIB-PUR was treated with butylamine in at least equimolar concentration to the MDI by adding 2,6-dimethylpyridine and 0.08 g of butylamine to 1 g of the PIB-PUR, and then shaken on a shaker table at 225 rpm at 30° C. for about 12 hours. The treated PIB-PUR solution was stored at room temperature in a sealed container and recharacterized after 24 hours and after 17 days. The results are also shown in Table 3. As shown in Table 3, the molecular weight of the treated PIB-PUR decreased significantly with the addition of the butylamine suggesting that at least some of the chemical cross-linking that had taken place over 21 days appeared to have been reversed with the addition of the butylamine. As further shown in Table 3, the cross-links did not reappear over an additional 17 days of storage.
  • TABLE 3
    PIB-PUR Mn Mw
    After 21 days 71,700 184,000
    24 hours after 65,970 159,000
    Butylamine
    Treatment
    17 days after 61,970 147,800
    Butylamine
    Treatment
  • A dynamic viscosity was measured for various concentrations of the FIB-FUR of Example 2 in 2,6-dimethylpyridine before treatment 44 and 24 hours after treatment 46 with the butylamine. Three PIB-PUR solutions of various concentrations were prepared for each of the before treatment 40 and after treatment 42 by adding appropriate amounts of 2,6-dimethylpyridine. The results are shown in FIG. 4 . As shown in FIG. 4 , the dynamic viscosity dropped significantly with the addition of the butylamine, again suggesting that at least some of the chemical cross-linking that had taken place over 24 days appeared to have been reversed with the addition of the butylamine.
  • Various modifications and additions can be made to the embodiments discussed without departing from the scope of this disclosure. For example, while the embodiments described above refer to particular features, the scope of this disclosure also includes embodiments having different combinations of features and embodiments that do not include all of the described features. Accordingly, the scope of this disclosure is intended to embrace all such alternatives, modifications, and variations as fall within the scope of the claims, together with all equivalents thereof.

Claims (16)

We claim:
1. A polymeric material comprising:
a polyisobutylene-polyurethane block copolymer including:
soft segments including a polyisobutylene diol residue;
hard segments including a diisocyanate residue; and
end groups bonded by urea bonds to a portion of the diisocyanate residue, the end groups including a residue of a mono-functional, primary amine having a C3 to C30 aliphatic straight chain.
2. The polymeric material of claim 1, wherein the soft segments are present in the copolymer in an amount of about 40% to about 70% by weight of the copolymer, and the hard segments are present in the copolymer in an amount of about 30% to about 60% by weight of the copolymer.
3. The polymeric material of claim 1, wherein the diisocyanate residue includes 4,4′-methylene diphenyl diisocyanate residue.
4. The polymeric material of claim 1, wherein the hard segments further include a chain extender residue.
5. The polymeric material of claim 4, wherein the chain extender residue is 1,4-butanediol residue.
6. The polymeric material of claim 1, wherein the soft segments further include at least one of: a polyether diol residue, a polyester dial residue, and a polycarbonate dial residue.
7. A medical device comprising:
a polymeric material including:
a polyisobutylene-polyurethane block copolymer including:
soft segments including a polyisobutylene diol residue;
hard segments including a diisocyanate residue; and
end groups bonded by urea bonds to a portion of the diisocyanate residue, the end groups including a residue of a mono-functional, primary amine having a C3 to C30 aliphatic straight chain.
8. The medical device of claim 7, wherein the soft segments are present in the copolymer in an amount of about 40% to about 70% by weight of the copolymer, and the hard segments are present in the copolymer in an amount of about 30% to about 60% by weight of the copolymer.
9. The medical device of claim 7, wherein the diisocyanate residue includes 4,4′-methylene diphenyl diisocyanate residue.
10. A method of making a polymeric material, the method comprising:
heating a mixture of soft segment components and hard segment components to an elevated temperature, the soft segment components including a polyisobutylene diol, and the hard segment components including a diisocyanate to form a prepolymer;
reacting a chain extender with the prepolymer to form a polymer; and
reacting an end capping agent with at least one of: the prepolymer and the polymer to form the polymeric material, wherein the end capping agent is a mono-functional, primary amine having a C3 to C30 aliphatic straight chain.
11. The method of claim 10, wherein the diisocyanate is in stoichiometric excess with respect to the polyisobutylene diol and the chain extender, and the mono-functional amine is in at least equimolar amount with respect to the diisocyanate.
12. The method of claim 10, wherein heating the mixture of the soft segment components and the hard segment components to an elevated temperature and reacting the chain extender with the heated mixture are in the presence of a tertiary amine catalyst.
13. The method of claim 10, wherein the diisocyanate includes 4,4′-methylene diphenyl diisocyanate.
14. The method of claim 10, wherein the soft segment components further include a polytetramethylene oxide diol, the diisocyanate is in stoichiometric excess with respect to the polyisobutylene diol, the chain extender, and the polytetramethylene oxide diol, and the mono-functional amine is in at least equimolar amount with respect to the diisocyanate.
15. The method of claim 10, wherein the end capping agent is reacted with the prepolymer to form the polymeric material.
16. The method of claim 10, wherein the end capping agent is reacted with the polymer to form the polymeric material.
US17/951,682 2018-01-17 2022-09-23 End-capped polyisobutylene polyurethane Active US11851522B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/951,682 US11851522B2 (en) 2018-01-17 2022-09-23 End-capped polyisobutylene polyurethane

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862618262P 2018-01-17 2018-01-17
US16/248,498 US11472911B2 (en) 2018-01-17 2019-01-15 End-capped polyisobutylene polyurethane
US17/951,682 US11851522B2 (en) 2018-01-17 2022-09-23 End-capped polyisobutylene polyurethane

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US16/248,498 Continuation US11472911B2 (en) 2018-01-17 2019-01-15 End-capped polyisobutylene polyurethane

Publications (2)

Publication Number Publication Date
US20230018482A1 true US20230018482A1 (en) 2023-01-19
US11851522B2 US11851522B2 (en) 2023-12-26

Family

ID=66334526

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/248,498 Active 2039-01-27 US11472911B2 (en) 2018-01-17 2019-01-15 End-capped polyisobutylene polyurethane
US17/951,682 Active US11851522B2 (en) 2018-01-17 2022-09-23 End-capped polyisobutylene polyurethane

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US16/248,498 Active 2039-01-27 US11472911B2 (en) 2018-01-17 2019-01-15 End-capped polyisobutylene polyurethane

Country Status (4)

Country Link
US (2) US11472911B2 (en)
EP (1) EP3740253B1 (en)
CN (1) CN111479596B (en)
WO (1) WO2019143629A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2385960B1 (en) 2009-01-12 2020-03-11 University Of Massachusetts Lowell Polyisobutylene-based polyurethanes
CN111479596B (en) 2018-01-17 2023-04-07 心脏起搏器股份公司 Blocked polyisobutylene polyurethanes

Family Cites Families (377)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2240558A (en) 1936-02-07 1941-05-06 Standard Oil Dev Co Nitrated diesel fuel and process of making same
US2182513A (en) 1936-05-14 1939-12-05 Standard Oil Co Method of sealing waxy surfaces
US2202877A (en) 1937-04-12 1940-06-04 Gulf Oil Corp Antioxidants and petroleum oils containing the same
US2451420A (en) 1943-07-28 1948-10-12 Du Pont Artificial yarns and process of producing the same
US2463452A (en) 1943-08-07 1949-03-01 Du Pont Adhesive compositions and adhesive sheets
US3069236A (en) 1955-03-10 1962-12-18 Aerojet General Co Method for the preparation of diborane
US3148028A (en) 1955-06-24 1964-09-08 Aerojet General Co Method for the preparation of diborane
BE635304A (en) 1962-07-25
US3328372A (en) 1964-05-11 1967-06-27 Exxon Research Engineering Co Soluble high molecular weight polymers of cyclopentadiene
NL6606553A (en) 1965-06-18 1967-11-13
BE759829A (en) 1969-12-03 1971-06-03 Upjohn Co PREPARATION OF POLYURETHANES
US3966624A (en) 1971-07-15 1976-06-29 Sun Oil Company Of Pennsylvania Blended traction fluid containing hydrogenated polyolefin and an adamantane ether
US3815611A (en) 1971-11-26 1974-06-11 Medtronic Inc Muscle stimulation and/or contraction detection device
US3755265A (en) 1972-04-04 1973-08-28 Nasa Highly fluorinated polyurethanes
US4118427A (en) 1973-02-13 1978-10-03 California Institute Of Technology Curable liquid hydrocarbon prepolymers containing hydroxyl groups and process for producing same
DE2418075A1 (en) 1974-04-13 1975-10-30 Bayer Ag Thermoplastic polyurethane elastomer prepn. - from high mol. wt. polyols, diisocyanates, chain-extending diols and alcohol or amine chain-breakers
GB1527592A (en) 1974-08-05 1978-10-04 Ici Ltd Wound dressing
US4157430A (en) 1975-05-05 1979-06-05 The Firestone Tire & Rubber Company Amine terminated polymers and the formation of block copolymers
US4157429A (en) 1975-05-05 1979-06-05 The Firestone Tire & Rubber Company Amine terminated polymers and the formation of block copolymers
US4154913A (en) 1975-05-05 1979-05-15 The Firestone Tire & Rubber Company Amine terminated polymers and the formation of blocked copolymers
GB1542319A (en) 1975-11-26 1979-03-14 Exxon Research Engineering Co Halogenated organoaluminium catalyst compositions and method of their preparation
US4145515A (en) 1976-12-01 1979-03-20 Congoleum Corporation Method of forming storage-stable polyurethane prepolymers
US4352359A (en) 1977-08-19 1982-10-05 Minnesota Mining And Manufacturing Company Biomedical electrode
US4230509A (en) 1979-04-13 1980-10-28 The United States Of America As Represented By The Secretary Of The Army Pyrophoric flame composition
US4304771A (en) 1979-07-13 1981-12-08 Usv Pharmaceutical Corporation Antihypertensive amides
US4342849A (en) 1979-09-10 1982-08-03 The University Of Akron Novel telechelic polymers and processes for the preparation thereof
US4316973A (en) 1979-09-10 1982-02-23 The University Of Akron Novel telechelic polymers and processes for the preparation thereof
US4276394A (en) 1979-09-10 1981-06-30 The University Of Akron Novel telechelic polymers, block copolymers and processes for the preparation thereof
US4539996A (en) 1980-01-23 1985-09-10 Minnesota Mining And Manufacturing Company Conductive adhesive and biomedical electrode
US4675361A (en) 1980-02-29 1987-06-23 Thoratec Laboratories Corp. Polymer systems suitable for blood-contacting surfaces of a biomedical device, and methods for forming
US5120813A (en) 1980-02-29 1992-06-09 Th. Goldschmidt Ag Moisture vapor permeable materials
US4686137A (en) 1980-02-29 1987-08-11 Thoratec Laboratories Corp. Moisture vapor permeable materials
US4861830A (en) 1980-02-29 1989-08-29 Th. Goldschmidt Ag Polymer systems suitable for blood-contacting surfaces of a biomedical device, and methods for forming
US4423185A (en) 1980-03-03 1983-12-27 Asahi Kasei Kogyo Kabushiki Kaisha Thermoplastic resinous composition
US4425264A (en) 1981-08-27 1984-01-10 International Flavors & Fragrances Inc. Branched chain ketones used in augmenting or enhancing the aroma of perfumes, colognes and perfumed articles and the like process for preparing same
US4374276A (en) 1981-08-27 1983-02-15 International Flavors & Fragrances Inc. Novel branched chain ketones and the process for preparing same
US4430233A (en) 1981-08-27 1984-02-07 International Flavors & Fragrances Inc. Branched chain ketones and uses thereof in augmenting or enhancing the aroma of perfumes, colognes and perfumed articles and the process for preparing same
IL64952A (en) 1982-02-08 1984-12-31 Bromine Compounds Ltd Intumescent fire retardant polymer compositions
US4484586A (en) 1982-05-27 1984-11-27 Berkley & Company, Inc. Hollow conductive medical tubing
US4420411A (en) 1982-06-04 1983-12-13 International Flavors & Fragrances Inc. Process for augmenting or enhancing the aroma of detergents using unsaturated branch chain ketones
US4477604A (en) 1982-09-20 1984-10-16 Oechsle Iii Sixtus J Polyurethane compositions and their use as luting agents
US4570270A (en) 1982-09-20 1986-02-18 Oechsle Iii Sixtus J Polyurethane compositions and their use as luting agents
US4621172A (en) 1982-12-22 1986-11-04 Nec Corporation Fast convergence method and system for echo canceller
US4486572A (en) 1983-07-06 1984-12-04 University Of Akron Synthesis of amphiphilic block copolymers and networks
US4518615A (en) 1983-08-23 1985-05-21 Warner-Lambert Company Non-adhesive chewing gum base composition
ZA841613B (en) 1984-03-02 1984-04-29 Thiokol Corporation Radiation curable coating for photographic laminate
US4508889A (en) 1984-07-19 1985-04-02 Desoto, Inc. Preparation of isocyanate-terminated polyurethanes containing amino silanes
US4767885A (en) 1984-08-06 1988-08-30 University Of Akron Sterically hindered binifers telechelic polymers made therefrom
JPS6173666A (en) 1984-09-19 1986-04-15 日本ゼオン株式会社 Polyurethane excellent in antithrombotic property and dynamical characteristics
GB2180123B (en) 1984-12-21 1989-01-18 Senezco Limited Transponder systems
US4888389A (en) 1985-02-05 1989-12-19 University Of Akron Amphiphilic polymers and method of making said polymers
US4982038A (en) 1985-03-19 1991-01-01 Phillips Petroleum Company Oxidative methylation of organic compounds
US4600652A (en) 1985-04-01 1986-07-15 Warner-Lambert Company Permanently bonded antithrombogenic polyurethane surface
US4910321A (en) 1985-06-20 1990-03-20 University Of Akron Living catalysts, complexes and polymers therefrom
WO1987004625A1 (en) 1986-01-30 1987-08-13 Vsesojuzny Nauchno-Issledovatelsky I Ispytatelny I Polyurethane foam composition for immobilization in traumatology
US5330520A (en) 1986-05-15 1994-07-19 Telectronics Pacing Systems, Inc. Implantable electrode and sensor lead apparatus
EP0275907A3 (en) 1987-01-23 1989-05-24 Mobay Corporation Rim polyurethane or polyurea compositions containing internal mold release agents
US5017664A (en) 1987-06-03 1991-05-21 Wisconsin Alumni Research Foundation Biocompatible polyurethane devices wherein polyurethane is modified with lower alkyl sulfonate and lower alkyl carboxylate
US4880883A (en) 1987-06-03 1989-11-14 Wisconsin Alumni Research Foundation Biocompatible polyurethanes modified with lower alkyl sulfonate and lower alkyl carboxylate
EP0295640B1 (en) 1987-06-18 1993-02-03 Dai-Ichi Kogyo Seiyaku Co., Ltd. Polyurethane composition
DE3722680A1 (en) 1987-07-09 1989-01-19 Leybold Ag Melting furnace with weight-dependent control of the melting block
US4752626A (en) 1987-08-27 1988-06-21 General Motors Corporation Method of making low compression set urethane foams
US5000875A (en) 1987-10-16 1991-03-19 E. I. Du Pont De Nemours And Company Conductive filled fluoropolymers
US5149739A (en) 1988-08-01 1992-09-22 The Bfgoodrich Company Fiber-reinforced thermoplastic elastomer polyurethane compositions with either modified and/or unmodified polyolefins
US5171760A (en) 1988-08-05 1992-12-15 Edison Polymer Innovation Corp. UV curable polymer formulation
EP0353471B1 (en) 1988-08-05 1994-01-05 Edison Polymer Innovation Corporation ( Epic) UV curable polymer formulation
IT1227065B (en) 1988-09-15 1991-03-14 Ausimont Spa FLUORINATED POLYURETHANE, CONTAINING RUBBER STRUCTURE BLOCKS POLIOS SIPERFLUOROALKYLENE RIGID HYDROGENATED BLOCKS, WITH IMPROVED MECHANICAL PROPERTIES.
JPH02202908A (en) 1989-02-02 1990-08-13 Nippon Zeon Co Ltd Urethane composition
US4939184A (en) 1989-03-07 1990-07-03 University Of Akron Polyurethane foam
EP0388480A1 (en) 1989-03-20 1990-09-26 Siemens Aktiengesellschaft Implantable stimulation electrode
US5433730A (en) 1989-05-03 1995-07-18 Intermedics, Inc. Conductive pouch electrode for defibrillation
US4928689A (en) 1989-05-15 1990-05-29 Cardiac Pacemakers, Inc. Rate adaptive cardiac pacer system having living cell tissue for sensing physiologic demand
US5029585A (en) 1989-07-14 1991-07-09 Baxter International Inc. Comformable intralumen electrodes
US5194505A (en) 1989-09-29 1993-03-16 E. I. Du Pont De Nemours And Company Chlorosulfonated polyolefin-modified polyurethane and polyurea compositions and process for making same
US5090422A (en) 1990-04-19 1992-02-25 Cardiac Pacemakers, Inc. Implantable electrode pouch
US5282844A (en) 1990-06-15 1994-02-01 Medtronic, Inc. High impedance, low polarization, low threshold miniature steriod eluting pacing lead electrodes
BR9003841A (en) 1990-08-06 1992-02-25 Sika S A POLYURETHANE RESIN, ADHESIVE, EPOXY RESIN, PROCESS FOR THE PRODUCTION OF THESE RESINS, INK AND USE
ES2097169T3 (en) 1990-08-16 1997-04-01 Basf Ag PROCEDURE FOR THE OBTAINING OF HYDROCARBONS AND POLYMERS WITH GROUPS CHLORIDE ALILIC TERMINALS.
JP2969470B2 (en) 1990-10-18 1999-11-02 鐘淵化学工業株式会社 Isobutylene polymer having allyl group at terminal and method for producing the same
US5129404A (en) 1990-12-21 1992-07-14 Intermedics, Inc. Implantable endocardial lead with retractable fixation apparatus
US5152299A (en) 1991-04-19 1992-10-06 Intermedics, Inc. Implantable endocardial lead with spring-loaded screw-in fixation apparatus
IT1252660B (en) 1991-12-23 1995-06-20 Ausimont Spa POLYURETHANE AND POLYURETHANE-UREE FLUORINATED AND PROCESSES FOR THEIR PREPARATION
DE4244812C2 (en) 1992-01-25 1998-05-28 Escher Wyss Gmbh Heated or cooled roller
EP0625998B1 (en) 1992-02-10 1996-06-05 Minnesota Mining And Manufacturing Company Radiation crosslinked elastomers
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US5589563A (en) 1992-04-24 1996-12-31 The Polymer Technology Group Surface-modifying endgroups for biomedical polymers
US5428123A (en) 1992-04-24 1995-06-27 The Polymer Technology Group Copolymers and non-porous, semi-permeable membrane thereof and its use for permeating molecules of predetermined molecular weight range
US5269810A (en) 1992-06-19 1993-12-14 W. L. Gore & Associates, Inc. Patch electrode
US5324324A (en) 1992-10-13 1994-06-28 Siemens Pacesetter, Inc. Coated implantable stimulation electrode and lead
US5322520A (en) 1992-11-12 1994-06-21 Implemed, Inc. Iontophoretic structure for medical devices
US5340881A (en) 1992-11-16 1994-08-23 The University Of Akron Aldehyde-telechelic polyisobutylenes, catalytic method for preparing the same with high conversion and selectivity, and block copolymers made thereform
CA2152604C (en) 1993-02-01 2000-05-09 Thomas M. Soukup An implantable electrode
DE4303556C1 (en) 1993-02-08 1994-10-27 Bayer Ag Hard polyurethanes or polyurethane foams
EP0612538A3 (en) 1993-02-22 1995-04-05 Cardiac Pacemakers Inc Metallized, implantable cardiac electrode.
US5385579A (en) 1993-03-30 1995-01-31 Siemens Pacesetter, Inc. Myocardial body implantable lead
GB9306887D0 (en) 1993-04-01 1993-05-26 Graham Neil B Random block copolymers
JPH06345821A (en) 1993-04-12 1994-12-20 Kanegafuchi Chem Ind Co Ltd Production of isobutylene-based polymer having unsaturated group
US5476496A (en) 1993-06-01 1995-12-19 Pacesetter Ab Implantable medical electrode system having an indifferent electrode formed as a part of the electrode insulator sleeve
JP3418434B2 (en) 1993-10-07 2003-06-23 鐘淵化学工業株式会社 Polymer having terminal functional group and method for producing the same
WO1995010544A1 (en) 1993-10-15 1995-04-20 University Of Massachusetts At Lowell Capping of living polymers
CA2174246C (en) 1993-10-29 2004-05-11 Gary R. Schildgen Method of manufacturing a medical electrical lead
JPH07330591A (en) 1994-06-06 1995-12-19 Kanegafuchi Chem Ind Co Ltd Percutaneously absorbable pharmaceutical preparation
JPH07331223A (en) 1994-06-06 1995-12-19 Kanegafuchi Chem Ind Co Ltd Adhesive composition for medical care
BE1008706A3 (en) 1994-09-28 1996-07-02 Cockerill Rech & Dev Product for the formation of a coating on a support and method of preparation of this product.
US5442010A (en) 1994-10-04 1995-08-15 Dow Corning Corporation Epoxy-terminated polyisobutylene-polydimethylsiloxane compositions
US5691062A (en) 1995-02-16 1997-11-25 Clemson University Molecularly bonded inherently conductive polymers on substrates and shaped articles thereof
CA2168938C (en) 1995-03-13 2010-06-01 Wolfgang Kaufhold A thermoplastic polyurethane resin
US5559067A (en) 1995-03-31 1996-09-24 Engelhard Corporation Modified microsphere FCC catalysts and manufacture thereof
GB9507393D0 (en) 1995-04-10 1995-05-31 Bp Chem Int Ltd Polyolefin diols
US5837313A (en) 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US5639847A (en) 1995-05-25 1997-06-17 Mearthane Products Corp. Preparation of conductive polyurethanes using a conductive quasi-solution
US5630844A (en) 1995-06-07 1997-05-20 Novamed Medical Products Manufacturing, Inc. Biocompatible hydrophobic laminate with thermoplastic elastomer layer
US5681514A (en) 1995-06-07 1997-10-28 Sulzer Intermedics Inc. Method for making an implantable conductive lead for use with a cardiac stimulator
US5663234A (en) 1995-06-15 1997-09-02 The University Of Akron Cationic multiblock thermoplastic elastomers
GB9513713D0 (en) 1995-07-05 1995-09-06 Exxon Chemical Patents Inc Curable elastomeric compositions and a process to produce curable elastomeric compositions
US6369123B1 (en) 1995-08-14 2002-04-09 3M Innovative Properties Company Radiation-crosslinkable elastomers and photocrosslinkers therefor
US5987746A (en) 1996-02-21 1999-11-23 Medtronic, Inc. Method of making medical electrical lead
DE19610350A1 (en) 1996-03-15 1997-09-18 Basf Ag Initiators for the anionically initiated polymerization of monomers having at least one ethylenically unsaturated group
US5912302A (en) 1996-06-11 1999-06-15 Gadkari; Avinash Chandrakant Elastomeric compositions and a process to produce elastomeric compositions
US5755762A (en) 1996-06-14 1998-05-26 Pacesetter, Inc. Medical lead and method of making and using
US5741331A (en) 1996-07-29 1998-04-21 Corvita Corporation Biostable elastomeric polymers having quaternary carbons
US5665823A (en) 1996-08-30 1997-09-09 Dow Corning Corporation Polyisobutylene polymers having acrylic functionality
US6200589B1 (en) 1996-09-13 2001-03-13 The University Of Akron Biological implants of semipermeable amphiphilic membranes
AUPO251096A0 (en) 1996-09-23 1996-10-17 Cardiac Crc Nominees Pty Limited Polysiloxane-containing polyurethane elastomeric compositions
EP0837097B1 (en) 1996-10-15 1999-08-11 Advanced Elastomer Systems, L.P. New block copolymers of polyolefins with polyurethanes, copolyesters or copolyamides and their use
US5874484A (en) 1997-01-30 1999-02-23 Shell Oil Company Use of polyol mixtures in rigid and semi-rigid polyurethane foams
EP0961796B1 (en) 1997-01-30 2002-05-02 KRATON Polymers Research B.V. Use of polyol mixtures in rigid and semi-rigid polyurethane foams
WO1998033832A1 (en) 1997-01-30 1998-08-06 Shell Internationale Research Maatschappij B.V. Use of polyol mixtures in rigid and semi-rigid polyurethane foams
US5796044A (en) 1997-02-10 1998-08-18 Medtronic, Inc. Coiled wire conductor insulation for biomedical lead
US6117554A (en) 1997-05-30 2000-09-12 Poly-Med, Inc. Modulated molecularly bonded inherently conductive polymers on substrates with conjugated multiple lamellae and shaped articles thereof
US5886089A (en) 1997-06-04 1999-03-23 Gfx Technologies, Inc. Grip and friction enhancement compositions
US6005051A (en) 1997-08-06 1999-12-21 The University Of Akron Multi-component polymeric networks containing polyisobutylene
US6072003A (en) 1997-08-25 2000-06-06 Advanced Elastomer Systems, L.P. Block copolymers of polyolefins with polyurethanes, copolyesters or copolyamides and their use
US20020012694A1 (en) 1997-09-17 2002-01-31 Alfred J. Moo-Young Transdermal administration of ment
JP3671624B2 (en) 1997-10-27 2005-07-13 株式会社カネカ Polyurethane elastic fiber
SE510868C2 (en) 1997-11-03 1999-07-05 Artimplant Dev Artdev Ab Molds for use as implants in human medicine and a method for making such molds
US5991667A (en) 1997-11-10 1999-11-23 Vitatron Medical, B.V. Pacing lead with porous electrode for stable low threshold high impedance pacing
US5902329A (en) 1997-11-14 1999-05-11 Pacesetter, Inc. Explantable lead
DE69822270T2 (en) 1997-11-14 2005-01-13 Sharp K.K. Method and device for the production of modified particles
JP3539544B2 (en) 1998-01-06 2004-07-07 シャープ株式会社 Surface modification method and surface modified particles
US6093197A (en) 1997-12-08 2000-07-25 Axon Engineering, Inc. Spiral nerve cuff electrode implantation tool
US5861023A (en) 1997-12-16 1999-01-19 Pacesetter, Inc. Thrombus and tissue ingrowth inhibiting overlays for defibrillator shocking coil electrodes
US5931862A (en) 1997-12-22 1999-08-03 Pacesetter, Inc. Medical lead and method of making and using with sodium sulfosuccinic ester
DE19800697B4 (en) 1998-01-10 2009-04-02 Biotronik Gmbh & Co. Kg Single electrode probe, especially for implantable defibrillators
EP1068252B1 (en) 1998-03-31 2005-11-23 Sekisui Chemical Co., Ltd. Polyesterurethane elastomers and process for their production
US6256541B1 (en) 1998-04-17 2001-07-03 Cardiac Pacemakers, Inc. Endocardial lead having defibrillation and sensing electrodes with septal anchoring
US20020138123A1 (en) 1998-04-21 2002-09-26 Medtronic, Inc. Medical electrical leads and indwelling catheters with enhanced biocompatibility and biostability
WO2000013058A1 (en) 1998-08-26 2000-03-09 Nissan Chemical Industries, Ltd. Treating agent for liquid crystal alignment layer and liquid crystal device using the same, and method for alignment of liquid crystal
CN1075103C (en) 1998-09-21 2001-11-21 深圳市奥博胶粘剂化工有限公司 Polyurethane adhesives/sealant composition, precursor and preparation process thereof
JP2000119363A (en) 1998-10-13 2000-04-25 Kanegafuchi Chem Ind Co Ltd Alcoholic hydroxyl-terminated hydrocarbon-based polymer and its production
US6361780B1 (en) 1998-11-12 2002-03-26 Cardiac Pacemakers, Inc. Microporous drug delivery system
JP4057174B2 (en) 1998-12-08 2008-03-05 株式会社カネカ Adhesive composition and method for producing adhesive product
JP2000264947A (en) 1999-03-18 2000-09-26 Asahi Chem Ind Co Ltd Curable composition
AU3919500A (en) 1999-03-23 2000-10-09 Carnegie Wave Energy Limited Catalytic processes for the controlled polymerization of free radically (co)polymerizable monomers and functional polymeric systems prepared thereby
JP3795697B2 (en) 1999-04-20 2006-07-12 株式会社カネカ Polyurethane elastic fiber
US6253110B1 (en) 1999-04-27 2001-06-26 Medtronic Inc Method for tissue stimulation and fabrication of low polarization implantable stimulation electrode
US6869466B2 (en) 1999-05-07 2005-03-22 Unisearch Limited Cucurbiturils and method for binding gases and volatiles using cucurbiturils
EP1061092A1 (en) 1999-06-17 2000-12-20 Shell Internationale Researchmaatschappij B.V. Process for the preparation of a rigid polyurethane foam.
JP2001011319A (en) 1999-06-30 2001-01-16 Kanegafuchi Chem Ind Co Ltd Curable composition
JP2001040064A (en) 1999-07-30 2001-02-13 Kanegafuchi Chem Ind Co Ltd Photocurable composition
US6284682B1 (en) 1999-08-26 2001-09-04 The University Of British Columbia Process for making chemically bonded sol-gel ceramics
US6363286B1 (en) 1999-09-24 2002-03-26 Cardiac Pacemakers, Inc. High impedance electrode assembly
JP2001131879A (en) 1999-10-25 2001-05-15 Kanegafuchi Chem Ind Co Ltd Artificial leather
JP4154815B2 (en) 1999-10-28 2008-09-24 ぺんてる株式会社 Bar code reader
US6228945B1 (en) 1999-12-20 2001-05-08 The University Of Akron Three arm star compositions of matter having diblock arms based on polyisobutylene and methods of preparation
US20010021743A1 (en) 1999-12-28 2001-09-13 Yuichiro Wakana Method of producing a graft copolymer
EP1275670B1 (en) 2000-01-21 2005-08-10 Mitsui Chemicals, Inc. Olefin block copolymers, production processes of the same and use thereof
US6426114B1 (en) 2000-05-02 2002-07-30 The University Of British Columbia Sol-gel calcium phosphate ceramic coatings and method of making same
US7013182B1 (en) 2000-05-04 2006-03-14 Cardiac Pacemakers, Inc. Conductive polymer sheath on defibrillator shocking coils
US6242058B1 (en) 2000-05-12 2001-06-05 Dow Corning Corporation Method for forming coatings from radiation curable compositions containing alkenyl ether functional polyisobutylenes
US6703433B1 (en) 2000-05-12 2004-03-09 Dow Corning Corporation Radiation curable compositions containing alkenyl ether functional polyisobutylenes
CN1443147A (en) 2000-05-19 2003-09-17 英属哥伦比亚大学 Process for making chemically bonded composite hydroxide ceramics
US6555619B1 (en) 2000-06-29 2003-04-29 The University Of Akron Physically crosslinked amphiphilic networks, methods of preparation, and uses thereof
WO2002013785A2 (en) 2000-08-14 2002-02-21 Pharmacia Corporation Drug delivery system with burst electrode
CN1234756C (en) 2000-10-18 2006-01-04 三井化学株式会社 Foam of thermoplastic urethane elastomer composition and process for producing the foam
TW541853B (en) 2000-11-10 2003-07-11 Sumitomo Chemical Co Polymeric fluorescent substance and polymer light-emitting device using the same
US6533955B1 (en) 2000-11-20 2003-03-18 3M Innovative Properties Company Conductive fluoropolymers
US6545097B2 (en) 2000-12-12 2003-04-08 Scimed Life Systems, Inc. Drug delivery compositions and medical devices containing block copolymer
JP3785931B2 (en) 2000-12-28 2006-06-14 日本電気株式会社 I / O request blocking method, I / O request blocking method, and recording medium recording I / O request blocking program
US6704604B2 (en) 2000-12-28 2004-03-09 Medtronic, Inc. System and method for promoting selective tissue in-growth for an implantable medical device
JP3808758B2 (en) 2001-03-22 2006-08-16 株式会社カネカ Method for producing isobutylene polymer
US7396582B2 (en) 2001-04-06 2008-07-08 Advanced Cardiovascular Systems, Inc. Medical device chemically modified by plasma polymerization
US6730324B2 (en) 2001-04-20 2004-05-04 The University Of British Columbia Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation
US7589132B2 (en) 2001-05-01 2009-09-15 Pentron Clinical Technologies, Llc Dental resins, dental composite materials, and method of manufacture thereof
US6653365B2 (en) 2001-05-01 2003-11-25 Pentron Clinical Technologies, Llc Dental composite materials and method of manufacture thereof
US7160941B2 (en) 2001-05-01 2007-01-09 Pentron Clinical Technologies, Llc Dental composite materials and method of manufacture thereof
US7470728B2 (en) 2001-05-01 2008-12-30 Pentron Clinical Technologies Llc Dental glazes and method of manufacture and use thereof
ITMI20011306A1 (en) 2001-06-21 2002-12-21 Ausimont Spa VULCANIZABLE POLYURETHANE
US7363091B1 (en) 2001-07-11 2008-04-22 Pacesetter Inc. Method of molding silicone elastomer drug carrier in an endocardial lead
US6600956B2 (en) 2001-08-21 2003-07-29 Cyberonics, Inc. Circumneural electrode assembly
US6852794B2 (en) 2001-09-07 2005-02-08 The Goodyear Tire & Rubber Company Rubber compound containing a polyhedral oligomeric silsesquioxanes
IN2014DN10834A (en) 2001-09-17 2015-09-04 Psivida Inc
US20030073961A1 (en) 2001-09-28 2003-04-17 Happ Dorrie M. Medical device containing light-protected therapeutic agent and a method for fabricating thereof
JP3969058B2 (en) 2001-10-31 2007-08-29 東ソー株式会社 Method for producing flexible polyurethane foam
US7187980B2 (en) 2001-11-09 2007-03-06 Oscor Inc. Cardiac lead with steroid eluting ring
WO2003042273A1 (en) 2001-11-14 2003-05-22 Medtronic, Inc. Compounds containing quaternary carbons, medical devices, and methods
EP1446437B1 (en) 2001-11-14 2015-04-15 Medtronic, Inc. Compounds containing quaternary carbons, medical devices, and methods
US6709514B1 (en) 2001-12-28 2004-03-23 Advanced Cardiovascular Systems, Inc. Rotary coating apparatus for coating implantable medical devices
DE10206123A1 (en) * 2002-02-14 2003-09-04 Wacker Chemie Gmbh Textile structures comprising organopolysiloxane / polyurea / polyurethane block copolymer
US6777026B2 (en) 2002-10-07 2004-08-17 Lord Corporation Flexible emissive coatings for elastomer substrates
US7196142B2 (en) 2002-04-04 2007-03-27 The University Of Akron Polyisobutylene-based block anionomers and cationomers and synthesis thereof
US20030236513A1 (en) 2002-06-19 2003-12-25 Scimed Life Systems, Inc. Implantable or insertable medical devices for controlled delivery of a therapeutic agent
US7292890B2 (en) 2002-06-20 2007-11-06 Advanced Bionics Corporation Vagus nerve stimulation via unidirectional propagation of action potentials
AUPS318202A0 (en) 2002-06-26 2002-07-18 Cochlear Limited Parametric fitting of a cochlear implant
US20040039437A1 (en) 2002-08-13 2004-02-26 Medtronic, Inc. Medical device exhibiting improved adhesion between polymeric coating and substrate
US7438925B2 (en) 2002-08-26 2008-10-21 Biovention Holdings Ltd. Drug eluting coatings for medical implants
DE10241853B3 (en) 2002-09-09 2004-01-22 Byk-Chemie Gmbh Polymeric urea urethane as a rheology control agent and manufacturing process
ATE406397T1 (en) 2002-09-17 2008-09-15 Medtronic Inc COMPOUNDS CONTAINING QUARTERNARY CARBON AND SILICON GROUPS, MEDICAL DEVICES AND METHODS
US20040063805A1 (en) 2002-09-19 2004-04-01 Pacetti Stephen D. Coatings for implantable medical devices and methods for fabrication thereof
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
US7231259B2 (en) 2002-10-04 2007-06-12 Pacesetter, Inc. Body implantable lead comprising electrically conductive polymer conductors
HUP0203632A3 (en) 2002-10-25 2005-08-29 Furukawa Electric Technologiai Recyclable crosslinked polymers with saturated main chain and thermally reversible urethane crosslink points
CA2505821C (en) 2002-11-12 2012-08-21 The Polymer Technology Group Incorporated Control of polymer surface molecular architecture via amphipathic endgroups
US6896965B1 (en) 2002-11-12 2005-05-24 Advanced Cardiovascular Systems, Inc. Rate limiting barriers for implantable devices
JP4160379B2 (en) 2002-12-26 2008-10-01 株式会社カネカ Thermoplastic elastomer composition
US20050043585A1 (en) 2003-01-03 2005-02-24 Arindam Datta Reticulated elastomeric matrices, their manufacture and use in implantable devices
US8016752B2 (en) 2003-01-17 2011-09-13 Gore Enterprise Holdings, Inc. Puncturable catheter
US6960207B2 (en) 2003-01-21 2005-11-01 St Jude Medical, Daig Division, Inc. Ablation catheter having a virtual electrode comprising portholes and a porous conductor
US20040147994A1 (en) 2003-01-28 2004-07-29 Cardiac Pacemakers, Inc. Tachy lead system optimized for septal placement
DE10303275A1 (en) 2003-01-28 2004-07-29 Basf Ag Functionalization of isobutene polymers, useful for the production of polyurethanes, comprises reaction of at least one isobutene polymer having terminal unsaturation with a hydroboration agent
US20050079199A1 (en) 2003-02-18 2005-04-14 Medtronic, Inc. Porous coatings for drug release from medical devices
US20080051866A1 (en) 2003-02-26 2008-02-28 Chao Chin Chen Drug delivery devices and methods
US6926919B1 (en) 2003-02-26 2005-08-09 Advanced Cardiovascular Systems, Inc. Method for fabricating a coating for a medical device
US7172575B2 (en) 2003-03-05 2007-02-06 Advanced Cardiovascular Systems, Inc. Catheter balloon having a lubricious coating
US20040186545A1 (en) 2003-03-20 2004-09-23 Rosero Spencer Z. Temporary percutaneous cardioverter-defibrillator
US7065411B2 (en) 2003-04-23 2006-06-20 Medtronic, Inc. Electrical medical leads employing conductive aerogel
GB0311121D0 (en) 2003-05-15 2003-06-18 Avecia Ltd Polyurethane dispersants
US20050060022A1 (en) 2003-05-21 2005-03-17 Felt Jeffrey C. Polymer stent
WO2004114732A1 (en) 2003-06-19 2004-12-29 World Properties, Inc. Material including a liquid crystalline polymer and a polyhedral oligomeric silsesquioxane (poss) filler
US6969744B2 (en) 2003-06-19 2005-11-29 University Of Southern Mississippi Living and quasiliving cationic telechelic polymers quenched by N-substituted pyrrole and methods for their preparation
CA2529420A1 (en) 2003-06-20 2004-12-29 Rudolf Faust End-capped polymer chains and products thereof
DE10328854A1 (en) 2003-06-26 2005-01-13 Basf Ag Process for the preparation of polyisobutenes
EP1639024A4 (en) 2003-07-01 2008-03-12 Univ Akron Akron Ohio Thermoplastic elastomeric multiblock copolymers of isobutylene and norbornene
US7364585B2 (en) 2003-08-11 2008-04-29 Boston Scientific Scimed, Inc. Medical devices comprising drug-loaded capsules for localized drug delivery
KR100579007B1 (en) 2003-08-13 2006-05-12 주식회사 루밴틱스 Photocurable and antistatic resin composition for optical fiber coating
US7953499B2 (en) 2003-09-30 2011-05-31 Cardiac Pacemakers, Inc. Drug-eluting electrode
US20050080470A1 (en) 2003-10-09 2005-04-14 Randy Westlund Intramyocardial lead implantation system and method
GB0323733D0 (en) 2003-10-10 2003-11-12 Univ Heriot Watt Conductive polymer
GB0326286D0 (en) 2003-11-11 2003-12-17 Vantico Gmbh Initiator systems for polymerisable compositions
US7807722B2 (en) 2003-11-26 2010-10-05 Advanced Cardiovascular Systems, Inc. Biobeneficial coating compositions and methods of making and using thereof
US7119138B1 (en) 2003-12-19 2006-10-10 Inmat Inc. Barrier coating of a mixture of cured and uncured elastomeric polymers and a dispersed layered filler in a liquid carrier and coated articles
GB0401202D0 (en) 2004-01-20 2004-02-25 Ucl Biomedica Plc Polymer for use in conduits and medical devices
GB2427408A (en) 2004-01-20 2006-12-27 World Properties Inc Circuit Materials Circuits Multi Layer Circuits And Method Of Manufacture
US7280875B1 (en) 2004-02-04 2007-10-09 Pacesetter, Inc. High strength, low resistivity electrode
US7056985B2 (en) 2004-02-11 2006-06-06 University Of Massachusetts Lowell End-capped polymer chains and products thereof
US20050180919A1 (en) 2004-02-12 2005-08-18 Eugene Tedeschi Stent with radiopaque and encapsulant coatings
US20070190108A1 (en) 2004-05-17 2007-08-16 Arindam Datta High performance reticulated elastomeric matrix preparation, properties, reinforcement, and use in surgical devices, tissue augmentation and/or tissue repair
US7105622B2 (en) 2004-06-02 2006-09-12 The University Of Akron Hybrid polyurethanes
US20050288476A1 (en) 2004-06-17 2005-12-29 Iskender Yilgor Thermoplastic copolymers through stoichiometric reactions between diisocyanates and oligomeric diols and diamines
CA2471006A1 (en) 2004-06-23 2005-12-23 Bayer Inc. Silica reinforced elastomer compounds prepared with dry liquid modifiers
JP2006274235A (en) 2004-07-30 2006-10-12 Fuji Photo Film Co Ltd Polymerizable composition, optically anisotropic layer, method for producing the same, optical compensatory element, liquid crystal display and liquid crystal projector
JP4155243B2 (en) 2004-08-04 2008-09-24 トヨタ自動車株式会社 Solenoid valve
US20060047083A1 (en) 2004-08-30 2006-03-02 Iskender Yilgor Triblock copolymers and their production methods
US7289856B1 (en) 2004-09-29 2007-10-30 Pacesetter, Inc. Medical electrical lead containing a pyroelectric material
US7347751B2 (en) 2004-09-30 2008-03-25 Cardiac Pacemakers, Inc. Cardiac lead implantation system
DE102004048991B4 (en) 2004-10-04 2010-01-28 Biotronik Crm Patent Ag electrode line
GB0428444D0 (en) 2004-12-29 2005-02-02 Cambridge Display Tech Ltd Conductive polymer compositions in opto-electrical devices
US8075906B2 (en) 2005-02-01 2011-12-13 Boston Scientific Scimed, Inc. Medical devices having polymeric regions with copolymers containing hydrocarbon and heteroatom-containing monomeric species
WO2006110647A1 (en) 2005-04-08 2006-10-19 University Of Massachusetts Lowell Research Foundation Capping reactions in cationic polymerization; kinetic and synthetic utility
US20060235499A1 (en) 2005-04-14 2006-10-19 Cardiac Pacemakers, Inc. Coated lead fixation electrode
US20060249446A1 (en) 2005-05-04 2006-11-09 Gary Yeager Solvent-resistant composite membrane composition
US20070051531A1 (en) 2005-09-08 2007-03-08 Harshad Borgaonkar Drug eluting coatings for a medical lead and method therefor
US7630749B2 (en) 2005-11-07 2009-12-08 Gore Enterprise Holdings, Inc. Implantable electrophysiology lead body
US7553546B1 (en) 2005-11-16 2009-06-30 Pacesetter, Inc. Polyethylene oxide and silicone copolymers and their usage on medical devices
US7715922B1 (en) 2005-11-16 2010-05-11 Pacesetter, Inc. Polyethylene oxide and polyisobutylene copolymers and their usage on medical devices
US8034874B2 (en) 2005-11-23 2011-10-11 Boston Scientific Scimed, Inc. Medical devices having polymeric regions that contain fluorocarbon-containing block copolymers
US20070122361A1 (en) 2005-11-29 2007-05-31 Weitao Jia Tooth colorant and whitener, method of manufacture, and method of use thereof
US20070128246A1 (en) 2005-12-06 2007-06-07 Hossainy Syed F A Solventless method for forming a coating
US20070142560A1 (en) 2005-12-21 2007-06-21 Young-Ho Song Block copolymer particles
US7501179B2 (en) 2005-12-21 2009-03-10 Boston Scientific Scimed, Inc. Block copolymer particles
US20070190104A1 (en) 2006-02-13 2007-08-16 Kamath Kalpana R Coating comprising an adhesive polymeric material for a medical device and method of preparing the same
US7981509B2 (en) 2006-02-13 2011-07-19 Donaldson Company, Inc. Polymer blend, polymer solution composition and fibers spun from the polymer blend and filtration applications thereof
US7465777B2 (en) 2006-03-02 2008-12-16 Boston Scientific Scimed, Inc. Hybrid polymer materials from reactive extrusion for medical devices
USD579758S1 (en) 2006-03-23 2008-11-04 Ykk Ap Inc. Sash lock
US7881808B2 (en) 2006-03-29 2011-02-01 Cardiac Pacemakers, Inc. Conductive polymeric coating with optional biobeneficial topcoat for a medical lead
US7737060B2 (en) 2006-03-31 2010-06-15 Boston Scientific Scimed, Inc. Medical devices containing multi-component fibers
US20070282411A1 (en) 2006-03-31 2007-12-06 Brian Franz Compliant electrical stimulation leads and methods of fabrication
WO2007117566A2 (en) 2006-04-07 2007-10-18 University Of Massachusetts Lowell Method to prepare block copolymers by the combination of cationic and anionic polymerization
EP2006328A4 (en) 2006-04-13 2011-03-02 Kaneka Corp Composition for rubber stoppers and rubber stoppers for medical use
US7689291B2 (en) 2006-05-01 2010-03-30 Cardiac Pacemakers, Inc. Lead with fibrous matrix coating and methods related thereto
US7727541B2 (en) 2006-05-18 2010-06-01 Boston Scientific Scimed, Inc. Medical devices having polymeric regions based on vinyl ether block copolymers
US7951194B2 (en) 2006-05-26 2011-05-31 Abbott Cardiovascular Sysetms Inc. Bioabsorbable stent with radiopaque coating
EP2022512A4 (en) 2006-05-31 2012-09-05 Kaneka Corp Catheter tube and catheter comprising the tube
US20080095918A1 (en) 2006-06-14 2008-04-24 Kleiner Lothar W Coating construct with enhanced interfacial compatibility
US9011516B2 (en) 2006-06-20 2015-04-21 Boston Scientific Scimed, Inc. Medical devices including composites
US9028859B2 (en) 2006-07-07 2015-05-12 Advanced Cardiovascular Systems, Inc. Phase-separated block copolymer coatings for implantable medical devices
DE102006037582A1 (en) 2006-08-11 2008-02-14 Bayer Materialscience Ag Antistatic and electrically conductive polyurethanes
US20080108773A1 (en) 2006-11-06 2008-05-08 Wicks Douglas A Polyurethane dispersions containing POSS nanoparticles
EP2094738B1 (en) 2006-11-17 2013-02-27 University Of Massachusetts Lowell Research Foundation Functional hydrocarbon polymers and process for producing same
US8163826B2 (en) 2006-11-21 2012-04-24 Schlumberger Technology Corporation Polymeric acid precursor compositions and methods
US20080124555A1 (en) 2006-11-29 2008-05-29 3M Innovative Properties Company Polymerizable composition comprising perfluoropolyether urethane having ethylene oxide repeat units
CN105628897A (en) 2006-11-30 2016-06-01 阿克伦大学 Polyisobutylenes and process for making same
US20160024340A1 (en) 2006-12-14 2016-01-28 Ppg Industries Ohio, Inc. Polyurethanes, articles and coatings prepared therefrom and methods of making the same
US20080167710A1 (en) 2007-01-05 2008-07-10 Vipul Bhupendra Dave Medical Device Having Regions With Various Agents Dispersed Therein and a Method for Making the Same
US20080175881A1 (en) 2007-01-18 2008-07-24 Boston Scientific Scimed, Inc. Blood-contacting medical devices for the release of nitric oxide and anti-restenotic agents
US20080194736A1 (en) 2007-02-13 2008-08-14 Minqiu Lu PVC nanocomposite manufacturing technology and applications
US20080208325A1 (en) 2007-02-27 2008-08-28 Boston Scientific Scimed, Inc. Medical articles for long term implantation
CA2680321C (en) 2007-03-09 2016-05-03 The University Of Akron Bio-artificial pancreas and a procedure for preparation of same
US8409348B2 (en) 2007-03-16 2013-04-02 Ube Industries, Ltd. Production method of zinc oxide single crystal
JP2008238761A (en) 2007-03-29 2008-10-09 Toyoda Gosei Co Ltd Polyurethane material and its manufacturing method
CA2683844C (en) 2007-04-12 2015-06-02 Joseph P. Kennedy Injectible cyanoacrylate-functionalized polyisobutylenes
CN101809062B (en) 2007-06-19 2014-05-28 阿克伦大学 Singly-terminated polyisobutylenes and process for making same
WO2009051945A1 (en) 2007-10-15 2009-04-23 Cardiac Pacemakers, Inc. Conductive composite electrode material
CA2704508A1 (en) 2007-11-01 2009-05-07 The University Of Akron Thermoplastic amphiphilic co-networks
JP2009132832A (en) 2007-11-30 2009-06-18 Asahi Glass Co Ltd One-component type polyurethane-based curable composition and adhesive using this
US20090156772A1 (en) 2007-12-12 2009-06-18 Boston Scientific Scimed, Inc. Melt processed materials for medical articles
FR2925061B1 (en) 2007-12-18 2010-01-15 Michelin Soc Tech RUBBER COMPOSITION, IN PARTICULAR FOR THE MANUFACTURE OF TIRES
FR2925062B1 (en) 2007-12-18 2011-03-04 Michelin Soc Tech RUBBER COMPOSITION, IN PARTICULAR FOR THE MANUFACTURE OF TIRES
US8349123B2 (en) 2008-04-01 2013-01-08 Henkel Corporation High heat resistant adhesive and sealant compositions
US20090292094A1 (en) 2008-05-21 2009-11-26 E. I. Dupont De Nemours And Company Fluoropolymer Composition
US8452258B2 (en) 2008-06-20 2013-05-28 Movirtu Limited Method and system to implement telephone billing to incentivize shared mobile phone usage
US20090326077A1 (en) 2008-06-27 2009-12-31 Cardiac Pacemakers, Inc. Polyisobutylene urethane, urea and urethane/urea copolymers and medical devices containing the same
WO2010033359A1 (en) 2008-09-19 2010-03-25 Cardiac Pacemakers, Inc. Surface modification to improve lubricity, abrasion resistance and temperature resilience of leads
US20110213084A1 (en) 2008-10-01 2011-09-01 The University Of Akron Polymers having both hard and soft segments, and process for making same
CN102341134B (en) * 2008-12-31 2014-09-10 波士顿科学医学有限公司 Copolymers having polyisobutylene and biodegradable polymer segments
US8285396B2 (en) 2009-01-05 2012-10-09 Kenergy, Inc. MRI compatible electrical lead for an implanted electronic medical device
EP2385960B1 (en) 2009-01-12 2020-03-11 University Of Massachusetts Lowell Polyisobutylene-based polyurethanes
AU2010226254B2 (en) 2009-03-17 2013-08-29 Cardiac Pacemakers, Inc. Porous fiber electrode coating and related methods
US8765238B2 (en) 2009-03-18 2014-07-01 Boston Scientific Scimed, Inc. Polymeric/inorganic composite materials for use in medical devices
US8155759B2 (en) 2009-03-20 2012-04-10 Innovia, Llc Pacemaker lead and method of making same
WO2010111280A1 (en) 2009-03-23 2010-09-30 University Of Massachusetts Lowell Functional polysobutylene based macromonomers and methods for making and using the same
EP2432513A2 (en) 2009-05-21 2012-03-28 Boston Scientific Scimed, Inc. Implantable medical devices for therapeutic agent delivery
EP2467174B1 (en) 2009-08-21 2018-09-26 Cardiac Pacemakers, Inc. Crosslinkable polyisobutylene-based polymers and medical devices containing the same
US20110051581A1 (en) 2009-08-25 2011-03-03 Seagate Technology Llc Vibration analysis methodology using data storage devices
US8644952B2 (en) 2009-09-02 2014-02-04 Cardiac Pacemakers, Inc. Medical devices including polyisobutylene based polymers and derivatives thereof
US8374704B2 (en) 2009-09-02 2013-02-12 Cardiac Pacemakers, Inc. Polyisobutylene urethane, urea and urethane/urea copolymers and medical leads containing the same
EP2499200A4 (en) 2009-11-11 2014-04-30 Univ Akron Polyisobutylene-based polyurethanes, polyureas and/or polyurethane-polyureas and method for making same
US20110152989A1 (en) * 2009-12-23 2011-06-23 Pacesetter, Inc. Soft abrasion-resistant polyisobutylene urethane copolymers
CN102741365A (en) 2010-01-21 2012-10-17 太阳化学公司 Low VOC solvent systems
WO2011127181A2 (en) 2010-04-06 2011-10-13 Syracuse University System and method for the release of nitric oxide using nanoscale media
WO2011133847A2 (en) 2010-04-22 2011-10-27 Syracuse University Polyhedral oligomeric silsesquioxane polyurethanes
FR2962368B1 (en) 2010-07-09 2012-08-31 Michelin Soc Tech PNEUMATIC OBJECT COMPRISING A GAS-SEALED LAYER BASED ON A MIXTURE OF A BUTYL RUBBER AND A THERMOPLASTIC ELASTOMER
US9611368B2 (en) 2010-10-15 2017-04-04 Evoqua Water Technologies Llc Process for making a monomer solution for making cation exchange membranes
EP3626341B1 (en) 2010-10-15 2021-06-09 Evoqua Water Technologies LLC Anion exchange membranes and process for making
BR112013010666B1 (en) 2010-11-11 2021-01-19 Dow Global Technologies Llc method for producing an insulating glass sealing unit based on polyurethane and insulating glass sealing unit based on polyurethane
JP5739007B2 (en) 2010-12-20 2015-06-24 カーディアック ペースメイカーズ, インコーポレイテッド Lead having conductive polymer conductor and method of manufacturing the same
JP5742226B2 (en) 2011-01-04 2015-07-01 凸版印刷株式会社 Gas barrier laminate, production method thereof, and gas barrier laminate film
WO2012116164A2 (en) 2011-02-23 2012-08-30 The University Of Akron Melt processible polyureas and polyurea-urethanes, method for the production thereof and products made therefrom
US20130041108A1 (en) 2011-05-19 2013-02-14 Joseph P. Kennedy Polymers having both hard and soft segments, and process for making same
WO2013003838A1 (en) 2011-06-30 2013-01-03 The University Of Akron Method for the synthesis of low cost initiators for telechelic polyisobutylenes
WO2013005004A1 (en) 2011-07-02 2013-01-10 Ucl Business Plc Implantable small diameter drainage conduit
JP2014525279A (en) 2011-08-12 2014-09-29 カーディアック ペースメイカーズ, インコーポレイテッド Method for coating devices using electrospinning and meltblowing methods
US9593271B2 (en) 2011-09-22 2017-03-14 Kaneka Corporation Curable composition and cured product thereof
CN102304679B (en) 2011-09-28 2013-01-30 宋玉军 Amorphous nanocrystal gradient functional material and preparation method thereof
WO2013055977A1 (en) 2011-10-13 2013-04-18 The Research Foundation Of State University Of New York Polymeric heart valve
FR2981937B1 (en) 2011-10-28 2013-11-08 Michelin Soc Tech ELASTOMERIC COMPOSITION HAVING VERY GOOD DISPERSION OF THE LOAD IN THE ELASTOMERIC MATRIX
US20130131765A1 (en) 2011-11-23 2013-05-23 Jeannette C. Polkinghorne Fibrous matrix coating materials
CN103987531A (en) 2011-12-12 2014-08-13 米其林集团总公司 Elastomeric composition having very good dispersion of the filler in the elastomeric matrix
FR2984340B1 (en) 2011-12-16 2018-01-12 Soc Tech Michelin TIRE HAVING AN EXTERNAL FLAN BASED ON A MIXTURE OF DIENE ELASTOMER AND THERMOPLASTIC ELASTOMER
FR2984339B1 (en) 2011-12-16 2018-01-12 Soc Tech Michelin PNEUMATIC HAVING A TREAD LINE BASED ON A MIXTURE OF DIENE ELASTOMER AND THERMOPLASTIC ELASTOMER
FR2984335B1 (en) 2011-12-16 2018-01-12 Societe De Technologie Michelin TIRE COMPRISING INTERNAL LAYER BASED ON A MIXTURE OF DIENE ELASTOMER AND THERMOPLASTIC ELASTOMER
JP5879146B2 (en) 2012-02-16 2016-03-08 積水化成品工業株式会社 Electrode pad
US8816028B2 (en) 2012-05-22 2014-08-26 Petrochemical Supply, Inc. Polyisobutylene composition having internal vinylidene and process for preparing the polyisobutylene polymer composition
PL3533792T3 (en) 2012-06-07 2021-11-29 Aragon Pharmaceuticals, Inc. Crystalline forms of an androgen receptor modulator
EP2875071A4 (en) * 2012-07-23 2015-12-23 Univ Akron Polyisobutylene-based polyurethanes containing organically modified montmorillonite
EP2895309B1 (en) 2012-09-11 2017-04-26 Cardiac Pacemakers, Inc. Method of forming an implantable medical device and medical electrical lead.
US20140096964A1 (en) 2012-10-10 2014-04-10 Baker Hughes Incorporated Nanoparticle modified fluids and methods of manufacture thereof
EP2922888B1 (en) 2012-11-21 2021-08-18 The University of Massachusetts High strength polyisobutylene polyurethanes
USD689734S1 (en) 2013-02-22 2013-09-17 Hamilton Beach Brands, Inc. Food processor
US9604281B2 (en) 2013-03-13 2017-03-28 Syracuse University Method to control void formation in nanomaterials using core/alloy nanoparticles with stainless interfaces
US9133394B2 (en) 2013-03-14 2015-09-15 Nanosys, Inc. Polyhedral oligomeric silsesquioxane nanocrystal stabilization ligands
US9688791B2 (en) 2013-07-17 2017-06-27 Basf Se High-reactivity polyisobutylene having a high content of vinylidene double bonds in the side chains
US9341948B2 (en) 2013-08-24 2016-05-17 Polyera Corporation Photopatternable materials and related electronic devices and methods
CN106659895B (en) 2014-07-11 2019-06-25 心脏起搏器股份公司 Polymer feedthrough component for chronic implantable device
CN104231207A (en) 2014-09-18 2014-12-24 苏州市雄林新材料科技有限公司 Recycled carbon fiber enhanced TPU (thermoplastic polyurethane) composite and preparation method thereof
CN104592850B (en) 2014-12-31 2017-06-23 三棵树涂料股份有限公司 The preparation method of ultra-hydrophilic transparent antifogging coating
CN104610902B (en) 2015-02-12 2018-01-30 厦门誉匠复合材料有限公司 Quick solidify afterwards polyurethane hot melt and preparation method thereof
AU2016251650A1 (en) 2015-04-23 2017-08-24 Cardiac Pacemakers, Inc. Compositions and methods for copolymer solutions with high weight percent copolymers
US10405975B2 (en) 2015-10-07 2019-09-10 Boston Scientific Scimed, Inc. Cultured cell leaflet material
EP3390482B1 (en) 2015-12-17 2021-03-03 Cardiac Pacemakers, Inc. Polyisobutylene-polyurethanes and medical devices containing the same
US10472457B2 (en) 2016-01-21 2019-11-12 The University Of Akron Initiators for living carbocationic polymerization
JP6756844B2 (en) 2016-05-10 2020-09-16 カーディアック ペースメイカーズ, インコーポレイテッド Thermosetting polyisobutylene-polyurethane and its manufacturing method
CN106129383B (en) 2016-09-05 2018-09-07 哈尔滨工业大学 A kind of ball-shaped lithium-ion battery anode material and its synthetic method with two phase gradient distributed architecture of nanoscale
EP3592786B1 (en) 2017-03-07 2023-05-10 Cardiac Pacemakers, Inc. Hydroboration/oxidation of allyl-terminated polyisobutylene
US10835638B2 (en) 2017-08-17 2020-11-17 Cardiac Pacemakers, Inc. Photocrosslinked polymers for enhanced durability
CN111479596B (en) 2018-01-17 2023-04-07 心脏起搏器股份公司 Blocked polyisobutylene polyurethanes
JP7102017B2 (en) 2020-10-27 2022-07-19 株式会社サンセイアールアンドディ Pachinko machine

Also Published As

Publication number Publication date
EP3740253B1 (en) 2023-08-16
WO2019143629A1 (en) 2019-07-25
EP3740253A1 (en) 2020-11-25
US11851522B2 (en) 2023-12-26
US20190218334A1 (en) 2019-07-18
US11472911B2 (en) 2022-10-18
CN111479596A (en) 2020-07-31
CN111479596B (en) 2023-04-07

Similar Documents

Publication Publication Date Title
US11851522B2 (en) End-capped polyisobutylene polyurethane
EP3390482B1 (en) Polyisobutylene-polyurethanes and medical devices containing the same
US11174336B2 (en) Polyisobutylene-based polyurethanes
EP0461375B1 (en) Crack-resistant polycarbonate urethane polymer prostheses
US5229431A (en) Crack-resistant polycarbonate urethane polymer prostheses and the like
US9050388B2 (en) In situ bonds
US8644952B2 (en) Medical devices including polyisobutylene based polymers and derivatives thereof
Kang et al. Polyisobutylene‐based polyurethanes with unprecedented properties and how they came about
AU2017263345B2 (en) Thermoset polyisobutylene-polyurethanes and methods for making
US9309347B2 (en) Bioresorbable thermoset polyester/urethane elastomers
WO1992004390A1 (en) Biostable polyurethane products
CN116057101A (en) Synthesis and use of high molecular weight and strength polyisobutylene-based polyurethanes

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: CARDIAC PACEMAKERS, INC., MINNESOTA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DELANEY, JOSEPH T., JR.;RO, ANDREW J.;WULFMAN, DAVID R.;AND OTHERS;SIGNING DATES FROM 20200810 TO 20201106;REEL/FRAME:062197/0151

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE